Document and Entity Information
Document and Entity Information | 12 Months Ended |
Dec. 31, 2018shares | |
Document and Entity Information [Abstract] | |
Entity Registrant Name | ProQR Therapeutics N.V. |
Entity Central Index Key | 0001612940 |
Document Type | 20-F |
Document Period End Date | Dec. 31, 2018 |
Amendment Flag | false |
Current Fiscal Year End Date | --12-31 |
Entity Well-known Seasoned Issuer | No |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Filer Category | Accelerated Filer |
Entity Common Stock, Shares Outstanding | 38,872,936 |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Shell Company | false |
Document Fiscal Year Focus | 2018 |
Document Fiscal Period Focus | FY |
Consolidated Statement of Finan
Consolidated Statement of Financial Position - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Assets | ||
Intangible assets | € 39 | |
Property, plant and equipment | € 1,864 | 2,505 |
Non-current assets | 1,864 | 2,544 |
Social securities and other taxes | 1,243 | 396 |
Prepayments and other receivables | 1,544 | 2,064 |
Cash and cash equivalents | 105,580 | 48,099 |
Current assets | 108,367 | 50,559 |
Total assets | 110,231 | 53,103 |
Shareholders’ equity | ||
Share capital | 1,726 | 1,457 |
Share premium | 235,744 | 148,763 |
Reserves | 10,888 | 8,513 |
Accumulated deficit | (155,443) | (119,370) |
Equity attributable to owners of the Company | 92,915 | 39,363 |
Non-controlling interests | (230) | (38) |
Total equity | 92,685 | 39,325 |
Liabilities | ||
Borrowings | 9,386 | 5,284 |
Non-current liabilities | 9,386 | 5,284 |
Borrowings | 1,960 | |
Trade payables | 135 | 546 |
Social security and other taxes | 1,019 | |
Pension premiums | 7 | |
Deferred income | 545 | 347 |
Other current liabilities | 7,473 | 4,622 |
Current liabilities | 8,160 | 8,494 |
Total liabilities | 17,546 | 13,778 |
Total equity and liabilities | € 110,231 | € 53,103 |
Consolidated Statement of Profi
Consolidated Statement of Profit or Loss and Comprehensive Income € in Thousands, $ in Thousands | 12 Months Ended | |||||
Dec. 31, 2018USD ($)shares | Dec. 31, 2018EUR (€)€ / sharesshares | Dec. 31, 2017USD ($)shares | Dec. 31, 2017EUR (€)€ / sharesshares | Dec. 31, 2016USD ($)shares | Dec. 31, 2016EUR (€)€ / sharesshares | |
Consolidated Statement of Profit or Loss and Comprehensive Income | ||||||
Other income | $ 5,761 | € 5,761 | $ 1,495 | € 1,495 | $ 1,828 | € 1,828 |
Research and development costs | (29,514) | (31,153) | (31,923) | |||
General and administrative costs | (12,540) | (10,840) | (9,478) | |||
Total operating costs | (42,054) | (41,993) | (41,401) | |||
Operating result | (36,293) | (40,498) | (39,573) | |||
Finance income and expense | (792) | (3,175) | 470 | |||
Result before corporate income taxes | (37,085) | (43,673) | (39,103) | |||
Corporate income taxes | $ (1) | (1) | $ (2) | (2) | ||
Result for the year | (37,086) | (43,675) | (39,103) | |||
Other comprehensive income | (28) | 151 | (16) | |||
Items that are or may be reclassified to profit or loss | ||||||
Foreign operations – foreign currency translation differences | (28) | 151 | (16) | |||
Total comprehensive loss (attributable to equity holders of the Company) | (37,114) | (43,524) | (39,119) | |||
Result attributable to | ||||||
Owners of the Company | (36,894) | (43,637) | (39,103) | |||
Non-controlling interests | (192) | (38) | ||||
Result for the year | € (37,086) | € (43,675) | € (39,103) | |||
Share information | ||||||
Weighted average number of shares outstanding | shares | 34,052,520 | 34,052,520 | 25,374,807 | 25,374,807 | 23,346,507 | 23,346,507 |
Earnings per share attributable to the equity holders of the Company (expressed in Euro per share) | ||||||
Basic and diluted loss per share | € / shares | € (1.08) | € (1.72) | € (1.67) |
Consolidated Statement of Chang
Consolidated Statement of Changes in Equity - EUR (€) € in Thousands | Share capital | Share Premium [Member] | Equity Settled Employee Benefit Reserve | Translation Reserve | Accumulated Deficit | Total | Non-controlling interests [Member] | Total |
Balance at beginning of period at Dec. 31, 2015 | € 934 | € 123,595 | € 1,899 | € 1 | € (36,630) | € 89,799 | € 89,799 | |
Result for the year | (39,103) | (39,103) | (39,103) | |||||
Other comprehensive income | (16) | (16) | (16) | |||||
Recognition of share-based payments | 2,454 | 2,454 | 2,454 | |||||
Shares options exercised | 2 | 2 | 2 | |||||
Balance at end of period at Dec. 31, 2016 | 934 | 123,597 | 4,353 | (15) | (75,733) | 53,136 | 53,136 | |
Result for the year | (43,637) | (43,637) | € (38) | (43,675) | ||||
Other comprehensive income | 151 | 151 | 151 | |||||
Recognition of share-based payments | 4,024 | 4,024 | 4,024 | |||||
Issue of ordinary shares | 343 | 25,342 | 25,685 | 25,685 | ||||
Issue of treasury shares | 180 | (180) | ||||||
Shares options exercised | 4 | 4 | 4 | |||||
Balance at end of period at Dec. 31, 2017 | 1,457 | 148,763 | 8,377 | 136 | (119,370) | 39,363 | (38) | 39,325 |
Result for the year | (36,894) | (36,894) | (192) | (37,086) | ||||
Other comprehensive income | (28) | (28) | (28) | |||||
Recognition of share-based payments | 4 | 2,185 | 3,224 | 5,413 | 5,413 | |||
Issue of ordinary shares | 265 | 83,926 | 84,191 | 84,191 | ||||
Shares options lapsed | (97) | 97 | ||||||
Shares options exercised | 870 | (724) | 724 | 870 | 870 | |||
Balance at end of period at Dec. 31, 2018 | € 1,726 | € 235,744 | € 10,780 | € 108 | € (155,443) | € 92,915 | € (230) | € 92,685 |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Cash flow from operating activities | |||
Net result | € (37,086) | € (43,675) | € (39,103) |
Adjustments for: | |||
Amortization & depreciation & Impairment | 992 | 1,065 | 1,245 |
Share-based payment expenses | 5,413 | 4,024 | 2,454 |
Financial income and expenses | 792 | 3,175 | (470) |
Net foreign exchange gain / (loss) | (28) | 151 | (16) |
Changes in working capital | 1,295 | 164 | 1,433 |
Corporate income tax paid | (1) | (2) | |
Interest received (paid) | 130 | 147 | 236 |
Net cash used in operating activities | (28,493) | (34,951) | (34,221) |
Cash flow from investing activities | |||
Purchases of property, plant and equipment | (312) | (121) | (2,539) |
Net cash used in investing activities | (312) | (121) | (2,539) |
Cash flow from financing activities | |||
Proceeds from issuance of shares, net of transaction costs | 84,191 | 25,685 | |
Proceeds from exercise of share options | 870 | 4 | 2 |
Proceeds from borrowings | 264 | 301 | 370 |
Proceeds from convertible loans | 1,132 | 650 | |
Redemption of financial lease | (15) | ||
Net cash generated by financing activities | 86,457 | 26,640 | 357 |
Net increase/(decrease) in cash and cash equivalents | 57,652 | (8,432) | (36,403) |
Currency effect cash and cash equivalents | (171) | (2,669) | 738 |
Cash and cash equivalents at the beginning of the year | 48,099 | 59,200 | 94,865 |
Cash and cash equivalents at the end of the year | € 105,580 | € 48,099 | € 59,200 |
General Information
General Information | 12 Months Ended |
Dec. 31, 2018 | |
General Information | |
General Information | PROQR THERAPEUTICS N.V. Notes to the Consolidated Financial Statements 1. General Information ProQR Therapeutics N.V., or “ProQR” or the “Company”, is a development stage company domiciled in the Netherlands that primarily focuses on the development and commercialization of novel therapeutic medicines. Since September 18, 2014, the Company’s ordinary shares are listed on the NASDAQ Global Market under ticker symbol PRQR. The Company was incorporated in the Netherlands, on February 21, 2012 and was reorganized from a private company with limited liability to a public company with limited liability on September 23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands. At December 31, 2018, ProQR Therapeutics N.V. is the ultimate parent company of the following entities: · ProQR Therapeutics Holding B.V. (the Netherlands, 100%); · ProQR Therapeutics I B.V. (the Netherlands, 100%); · ProQR Therapeutics II B.V. (the Netherlands, 100%); · ProQR Therapeutics III B.V. (the Netherlands, 100%); · ProQR Therapeutics IV B.V. (the Netherlands, 100%); · ProQR Therapeutics VI B.V. (the Netherlands, 100%); · ProQR Therapeutics VII B.V. (the Netherlands, 100%); · ProQR Therapeutics VIII B.V. (the Netherlands, 100%); · ProQR Therapeutics IX B.V. (the Netherlands, 100%); · ProQR Therapeutics I Inc. (United States, 100%); · Amylon Therapeutics B.V. (the Netherlands, 80%); · Amylon Therapeutics, Inc. (Unites States, a 100% subsidiary of Amylon Therapeutics B.V.) ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (“ESOP Foundation”) and has full control over this entity. As used in these consolidated financial statements, unless the context indicates otherwise, all references to “ProQR”, the “Company” or the “Group” refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation. |
Basis of Preparation
Basis of Preparation | 12 Months Ended |
Dec. 31, 2018 | |
Basis of Preparation | |
Basis of Preparation | 2. Basis of preparation (a) Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the IASB. (b) Basis of measurement The financial statements have been prepared on the historical cost basis except for financial instruments and share-based payment obligations which have been based on fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets. (c) Functional and presentation currency These consolidated financial statements are presented in euro, which is the Company’s functional currency. All amounts have been rounded to the nearest thousand, unless otherwise indicated. (d) Going Concern The management board of ProQR has, upon preparing and finalizing the 2018 financial statements, assessed the Company’s ability to fund its operations for a period of at least one year after the date of signing these financial statements. The management board of the Company is confident about the continuity of the Company based on its existing funding, taking into account the Company’s current cash position and the projected cash flows based on the activities under execution on the basis of ProQR’s business plan and budget. (e) Use of estimates and judgements In preparing these consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Information about assumptions and estimation uncertainties that may have a significant risk of resulting in a material adjustment is included below. (i) Share-based payments Share options granted to employees and consultants are measured at the fair value of the equity instruments granted. Fair value is determined through the use of an option-pricing model considering, among others, the following variables: a) the exercise price of the option; b) the expected life of the option; c) the current value of the underlying shares; d) the expected volatility of the share price; e) the dividends expected on the shares; and f) the risk-free interest rate for the life of the option. For the Company’s share option plans, management’s judgment is that the Black-Scholes valuation method is the most appropriate for determining the fair value of the Company’s share options. Initially, the Company’s ordinary shares were not publicly traded and consequently the Company needed to estimate the fair value of its share and the expected volatility of that value. The expected volatility of all options granted was therefore based on the average historical volatility of the Company’s peers over a period that agrees with the expected option life. All assumptions and estimates are further discussed in Note 12(d) to the financial statements. The value of the underlying shares was determined on the basis of the prior sale of company stock method. As such, the Company has benchmarked the value per share to external transactions of Company shares and external financing rounds. For options granted from the moment of listing as stated above, the Company uses the closing price of the ordinary shares on the previous business day as exercise price of the options granted. The result of the share option valuations and the related compensation expense is dependent on the model and input parameters used. Even though Management considers the fair values reasonable and defensible based on the methodologies applied and the information available, others might derive a different fair value for the Company’s share options. (ii) Corporate income taxes The Company recognizes deferred tax assets arising from unused tax losses or tax credits only to the extent that the Company has sufficient taxable temporary differences or there is convincing evidence that sufficient taxable profit will be available against which the unused tax losses or unused tax credits can be utilized. Management’s judgment is that such convincing evidence is currently not sufficiently available and a deferred tax asset is therefore only recognized to the extent that the Company has sufficient taxable temporary differences. (iii) Grant income (Government) Grant income is not recognized until there is reasonable assurance that the Company will comply with the conditions attached to them. (Government) Grants are recognized in profit or loss on a systematic basis over the period the Company recognizes as expenses the related costs for which the grants are expected to compensate. (iv) Research and development expenditures Research expenditures are currently not capitalized but are reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed. Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period. (f) Changes in accounting policies The financial statements have been prepared on the basis of International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”). IFRS 9 IFRS 9 contains three principal classification categories for financial assets: measured at amortized cost, FVOCI and FVTPL. The classification of financial assets under IFRS 9 is generally based on the business model in which a financial asset is managed and its contractual cash flow characteristics. IFRS 9 eliminates the previous IAS 39 categories of held to maturity, loans and receivables and available for sale. IFRS 9 largely retains the existing requirements in IAS 39 for the classification and measurement of financial liabilities. The adoption of IFRS 9 has not had a significant effect on the Group’s accounting policies related to financial liabilities and derivative financial instruments. Other new Standards and Interpretations, which became effective as of January 1, 2018, did not have a material impact on our financial statements. |
Significant Accounting Policies
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2018 | |
Significant Accounting Policies | |
Significant Accounting Policies | 3. Significant Accounting Policies The Company has consistently applied the following accounting policies to all periods presented in these consolidated financial statements. (a) Basis of consolidation (i) Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it has power over the entity, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The Group reassesses whether or not it controls an entity if facts and circumstances indicate that there are changes to one or more of these elements. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. (ii) Non-controlling interests (“NCI”) NCI are measured at their proportionate share of the acquiree's identifiable net assets at the acquisition date. Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. (iii) Loss of control When the Group loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any non-controlling interests and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost. (iv) Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated. Unrealized gains arising from transactions with equity-accounted investees are eliminated against the investment to the extent of the Group’s interest in the investee. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment. (b) Classes of financial instruments Financial instruments are both primary financial instruments, such as receivables and payables, and financial derivatives. For primary financial instruments, reference is made to the treatment per the corresponding balance sheet item. Financial derivatives are valued at fair value. Upon first recognition, financial derivatives are recognized at fair value and then revalued as at balance sheet date. (c) Foreign currencies (i) Foreign currency transactions Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are translated into the functional currency at the exchange rate when the fair value was determined. Foreign currency differences are generally recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not translated. (ii) Foreign operations The assets and liabilities of foreign operations are translated into euro at exchange rates at the reporting date. The income and expenses of foreign operations are translated into euros at the exchange rates at the dates of the transactions. Foreign currency differences are recognized in OCI and accumulated in the translation reserve, except to the extent that the translation difference is allocated to NCI. (d) Recognition of other income Other income includes amounts earned from third parties and are recognized when earned in accordance with the substance and under the terms of the related agreements and when it is probable that the economic benefits associated with the transaction will flow to the entity and the amount of the income can be measured reliably. The grants are recognized in other income on a systematic basis over the period the Company recognizes as expenses the related costs for which the grants are expected to compensate. (e) Government grants — WBSO The WBSO (“afdrachtvermindering speur- en ontwikkelingswerk”) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform research and development activities (as defined in the WBSO Act). Under this Act, a contribution is paid towards the labor costs of employees directly involved in research and development. The contribution is in the form of a reduction of payroll taxes and social security contributions recognized on a net basis within the labor costs. Subsidies relating to labor costs are deferred and recognized in the income statement in the period necessary to match them with the labor costs that they are intended to compensate. (f) Employee benefits (i) Short-term employee benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. (ii) Share-based payment transactions The grant-date fair value of equity-settled share-based payment awards granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. (iii) Pension obligations The Company operates defined contribution pension plans for all employees funded through payments to insurance companies. The Company has no legal or constructive obligation to pay further contributions once the contributions have been paid. The contributions are recognized as employee benefit expense when employees have rendered the service entitling them to the contributions. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. (g) Taxation Income tax expense represents the sum of the tax currently payable and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in OCI. (i) Current tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred tax Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Since the Company does not expect to be profitable in the foreseeable future, its deferred tax assets are valued at nil. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. (h) Intangible assets (i) Licenses Acquired patents have a finite useful life and are carried at cost less accumulated amortization and impairment losses. Amortization is calculated using the straight-line method to allocate the cost of patents over their estimated useful lives (generally 10 years unless a patent expires prior to that date). Amortization begins when an asset is available for its intended use. (ii) Research and development Research expenditures are recognized as expenses as incurred. Costs incurred on development projects are recognized as intangible assets as of the date that it can be established that it is probable that future economic benefits that are attributable to the asset will flow to the Company considering its commercial and technological feasibility, generally when filed for regulatory approval for commercial production, and when costs can be measured reliably. Given the current stage of the development of the Company’s products no development expenditures have yet been capitalized. Registration costs for patents are part of the expenditures for the research and development project. Therefore, registration costs for patents are expensed as incurred as long as the research and development project concerned does not yet meet the criteria for capitalization. (iii) Other intangible assets Other intangible assets, including software, that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. (iv) Amortization Amortization is calculated to write off the cost of intangible assets less their estimated residual values using the straight-line method over their estimated useful lives, and is recognized in profit or loss. The estimated useful lives for current and comparative periods are as follows: software: years; Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. (i) Property, plant and equipment (i) Recognition and measurement Items of property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment. Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss. (ii) Depreciation Depreciation is calculated to write off the cost of items of property, plant and equipment less their estimated residual values using the straight-line method over their estimated useful lives, and is recognized in profit or loss. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. The estimated useful lives of property, plant and equipment for current and comparative periods are as follows: leasehold improvements: 5-10 years; laboratory equipment: years; other: 3-5 years. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. (j) Impairment of tangible and intangible assets At the end of each reporting period, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Where a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified. Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. The recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. (k) Financial assets All financial assets are recognized and derecognized on the trade date where the purchase or sale of a financial asset is under a contract whose terms require delivery of the financial asset within the timeframe established by the market concerned, and are initially measured at fair value and subsequently measured at amortized cost or fair value on the basis of the entity’s business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. Specifically: · debt instruments that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal amount outstanding, are measured subsequently at amortised cost, and · all other debt investments and equity investments are measured subsequently at fair value through profit or loss (FVTPL). (l) Contract receivables Contract receivables, loans and other receivables that have fixed or determinable payments that are not quoted in an active market are classified as “loans and receivables”. Loans and receivables are measured at amortized cost using the effective interest method, less any impairment. The group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due. Trade receivables are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater than 120 days past due. Impairment losses on trade receivables and contract assets are presented as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same line item. Previous accounting policy for impairment of trade receivables In the prior year, an allowance for doubtful accounts is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the trade receivable is impaired. Loans and receivables are included in ‘current assets’, except for maturities greater than 12 months after the balance sheet date, which are classified as ‘non-current assets’. (m) Cash and cash equivalents Cash and cash equivalents include cash on hand and all highly liquid investments with original maturities of three months or less that are convertible to a known amount of cash and bear an insignificant risk of change in value. (n) Financial liabilities and equity instruments Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangement. Equity instruments An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs. Compound financial instruments Compound financial instruments issued by the Group comprise convertible notes denominated in euro that can be converted to share capital at the option of the holder, when the number of shares to be issued is fixed and does not vary with changes in fair value. The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversion option. The equity component is recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not remeasured. Interest related to the financial liability is recognized in profit or loss. On conversion, the financial liability is reclassified to equity and no gain or loss is recognized. Other financial liabilities Other financial liabilities, including borrowings, are initially measured at fair value, net of transaction costs incurred, and are subsequently measured at amortized cost using the effective interest method, with interest expense recognized on an effective yield basis. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period. Borrowings and other financial liabilities are classified as ‘non-current liabilities,’ other than liabilities with maturities up to one year, which are classified as “current liabilities”. The Company derecognizes financial liabilities when the liability is discharged, cancelled or expired. For all financial liabilities, the fair value approximates its carrying amount. (o) Leases (i) Determining whether an arrangement contains a lease At inception of an arrangement, the Company determines whether such an arrangement is or contains a lease. At inception or on reassessment of an arrangement that contains a lease, the Company separates payments and other consideration required by such an arrangement into those for the lease and those for other elements on the basis of their relative fair values. If the Company concludes for a finance lease that it is impracticable to separate the payments reliably, then an asset and a liability are recognized at an amount equal to the fair value of the underlying asset. Subsequently, the liability is reduced as payments are made and an imputed finance cost on the liability is recognized using the Company’s incremental borrowing rate. (ii) Leased assets Assets held by the Company under leases that transfer to the Company substantially all of the risks and rewards of ownership are classified as finance leases. The leased assets are measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the assets are accounted for in accordance with the accounting policy applicable to that asset. Assets held under other leases are classified as operating leases and are not recognized in the Company’s statement of financial position. (iii) Lease payments Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease. Minimum lease payments made under finance leases are apportioned between the finance expense and the reduction of the outstanding liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability. |
New standards and interpretatio
New standards and interpretations not yet adopted | 12 Months Ended |
Dec. 31, 2018 | |
New standards and interpretations not yet adopted | |
New standards and interpretations not yet adopted | 4. New standards and interpretations not yet adopted A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January 1, 2019, and have not been applied in preparing these consolidated financial statements. Those which may be relevant to the Group are set out below. The Group does not plan to adopt these standards early. IFRS 16 Leases IFRS 16 specifies how a company will recognize, measure, present and disclose leases. The standard provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. Lessors continue to classify leases as operating or finance, with IFRS 16’s approach to lessor accounting substantially unchanged from its predecessor, IAS 17. The impact on the income statement is that current operating expenses will be replaced by depreciation and interest. Total expenses (depreciation for 'right of use' assets and interest on lease liabilities) are higher in the earlier years of a typical lease and lower in the later years, in comparison with current accounting for operating leases. The main impact on the statement of cash flows is higher cash flows from operating activities, since cash payments for the principal part of the lease liability are classified in the net cash flow from financing activities by approximately € 1.2 million. IFRS 16 is effective for annual reporting periods beginning on or after January 1, 2019, with early adoption permitted and is expected to have an effect on our balance sheet of approximately € 2.3 million. There are no other standards that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions. |
Financial Risk Management
Financial Risk Management | 12 Months Ended |
Dec. 31, 2018 | |
Financial Risk Management | |
Financial Risk Management | 5. Financial Risk Management 5.1 Financial risk factors The Company’s activities expose it to a variety of financial risks: market risk (including currency risk, interest rate risk and price risk), credit risk and liquidity risk. The Company’s overall financial risk management seeks to minimize potential adverse effects resulting from unpredictability of financial markets on the Company’s financial performance. Risk management is carried out by the finance department. The finance department identifies and evaluates financial risks and proposes mitigating actions if deemed appropriate. (a) Market risk Market risk is the risk that changes in market prices – such as foreign exchange rates, interest rates and equity prices – will affect the Company’s income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. Foreign exchange risk Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities in foreign currencies, primarily with respect to the U.S. Dollar. The Company has an exposure associated with the time delay between entering into a contract, budget or forecast and the realization thereof. The Company operates a foreign exchange policy to manage the foreign exchange risk against the functional currency based on the Company’s cash balances and the projected future spend per major currency. At December 31, 2018 there was a net liability in U.S. Dollars of € 0.1 million (2017: € 0.7 million). Foreign currency denominated receivables and trade payables are short term in nature (generally 30 to 45 days). As a result foreign exchange rate movements on receivables and trade payables, during the years presented had an immaterial effect on the financial statements. At year-end, a substantial amount of our cash balances are denominated in U.S. Dollars. This amount reflects our current expectation of future expenditure in U.S. dollars. A reasonably possible weakening of the U.S. Dollar by 10% against all other currencies at December 31, 2018 would have affected the measurement of our cash balances denominated in a U.S. Dollar and affected equity and profit or loss by € 2.4 million (2017: € 2.5 million). The analysis assumes that all other variables, in particular interest rates, remain constant. Price risk The market prices for the production of preclinical and clinical materials and services as well as external contracted research may vary over time. Currently, the commercial prices of any of the Company’s product candidates is uncertain. When the development products near the regulatory approval date or potential regulatory approval date, the uncertainty of the potential sales price decreases. The Company is not exposed to commodity price risk. Furthermore the Company does not hold investments designated for sale, therefore are not exposed to equity securities price risk. Cash flow and fair value Interest rate risk The Company’s exposure to interest rate risks is limited due to the use of loans with fixed rates. The Company has several loans with fixed interest rates, totaling €9,386,000 at December 31, 2018 (2017: € 7,244,000). Details on the interest rates and maturities of these loans are provided in Note 13. (b) Credit risk Credit risk represents the risk of financial loss caused by default of the counterparty. The Company has no large receivables balances with external parties. The Company’s principal financial assets are cash and cash equivalents which are held at ABN Amro, Rabobank and Wells Fargo. Our cash management policy is focused on preserving capital, providing liquidity for operations and optimizing yield while accepting limited risk (Short-term credit ratings must be rated A‑1/P‑1/F1 at a minimum by at least one of the Nationally Recognized Statistical Rating Organizations (NRSROs) specifically Moody’s, Standard & Poor’s or Fitch. Long-term credit rating must be rated A2 or A at a minimum by at least one NRSRO). At December 31, 2018 and December 31, 2017, substantially all of our cash and cash equivalents were held at three large institutions, Rabobank, ABN Amro and Wells Fargo. All institutions are highly rated (ratings of Aa3, A1 and A2 for Rabobank, ABN Amro and Wells Fargo respectively) with sufficient capital adequacy and liquidity metrics. There are no financial assets past due date or impaired. No credit limits were exceeded during the reporting period. (c) Liquidity risk Liquidity risk represents the risk that an entity will encounter difficulty in meeting obligations associated with its financial liabilities. Prudent liquidity risk management implies ensuring sufficient availability of cash resources for funding of operations and planning to raise cash if and when needed, either through issue of shares or through credit facilities. Management monitors rolling forecasts of the Company’s liquidity reserve on the basis of expected cash flow. The table below analyzes ProQR’s undiscounted liabilities into relevant maturity groupings based on the remaining period at year-end until the contractual maturity date: Less than Between 1 Between 2 1 year and 2 years and 5 years Over 5 years (€ in thousands) At December 31, 2018 Borrowings — 8,984 — Trade payables and other payables 8,160 — — — Total 8,160 797 8,984 — At December 31, 2017 Borrowings 1,960 980 5,981 — Trade payables and other payables 6,534 — — — Total 8,494 980 5,981 — 5.2 Capital risk management The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders, benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders (although at this time the Company does not have retained earnings and is therefore currently unable to pay dividends), return capital to shareholders, issue new shares or sell assets to reduce debt. The total amount of equity as recorded on the balance sheet is managed as capital by the Company. 5.3 Fair value measurement For financial instruments that are measured on the balance sheet at fair value, IFRS 13 requires disclosure of fair value measurements by level of the following fair value measurement hierarchy: · quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1); · inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2); and · inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3). The carrying amount of all financial assets and financial liabilities is a reasonable approximation of the fair value and therefore information about the fair values of each class has not been disclosed. |
Segment Information
Segment Information | 12 Months Ended |
Dec. 31, 2018 | |
Segment Information | |
Segment Information | 6. Segment Information The Company operates in one reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics. The management board is identified as the chief operating decision maker. The management board reviews the operating results regularly to make decisions about resources and to assess overall performance. The Company has not generated any sales revenues since inception. All non-current assets of the Company are located in the Netherlands. The amounts provided to the management board with respect to total assets and liabilities are measured in a manner consistent with that of the financial statements. |
Intangible Assets
Intangible Assets | 12 Months Ended |
Dec. 31, 2018 | |
Intangible Assets | |
Intangible Assets | 7. Intangible Assets Licenses Software Total (€ in thousands) (€ in thousands) (€ in thousands) Balance at January 1, 2017 Cost 39 152 191 Accumulated amortization — (101) (101) Carrying amount 39 51 90 Additions — — — Amortization — (51) (51) Movement for the period — (51) (51) Balance at December 31, 2017 Cost 39 152 191 Accumulated amortization — (152) (152) Carrying amount 39 — 39 Additions — — — Impairment (39) — (39) Amortization — — — Movement for the period (39) — (39) Balance at December 31, 2018 Cost 39 152 191 Accumulated amortization (39) (152) (191) Carrying amount — — — In 2012, the Company acquired an exclusive license from the Massachusetts General Hospital. The initial payment in respect of the license, in the amount of € 39,000 has been impaired and is included in the general and administrative costs for an amount of € 39,000 (2017: € -). The amortization charge for 2018 is included in the general and administrative costs for an amount of € - (2017: € 51,000). |
Property, Plant and Equipment (
Property, Plant and Equipment ('PP&E') | 12 Months Ended |
Dec. 31, 2018 | |
Property, Plant and Equipment ('PP&E") | |
Property, Plant and Equipment ('PP&E') | 8. Property, Plant and Equipment (‘PP&E’) Leasehold Laboratory improvements equipment Other Total (€ in thousands) (€ in thousands) (€ in thousands) (€ in thousands) Balance at January 1, 2017 Cost 1,847 1,957 1,283 5,087 Accumulated depreciation (508) (660) (481) (1,649) Carrying amount 1,339 1,297 802 3,438 Additions 9 47 26 82 Depreciation (294) (409) (312) (1,015) Transfer — — — — Disposals — — — — Movement for the period (285) (362) (286) (933) Balance at December 31, 2017 Cost 1,856 2,004 1,309 5,169 Accumulated depreciation (802) (1,069) (793) (2,664) Carrying amount 1,054 935 516 2,505 Additions 18 281 13 312 Depreciation (296) (419) (238) (953) Disposals — — — — Movement for the period (278) (138) (225) (641) Balance at December 31, 2018 Cost 1,874 2,285 1,322 5,481 Accumulated depreciation (1,098) (1,488) (1,031) (3,617) Carrying amount 776 797 291 1,864 The depreciation charge for 2018 is included in the research and development costs for an amount of € 725,000 (2017: € 836,000) and in the general and administrative costs for an amount of € 228,000 (2017: € 179,000). |
Social Security and Other Taxes
Social Security and Other Taxes | 12 Months Ended |
Dec. 31, 2018 | |
Social Security and Other Taxes | |
Social Security and Other Taxes | 9. Social Security and Other Taxes December 31, December 31, 2018 2017 (€ in thousands) Value added tax 311 396 Wage tax 932 — 1,243 396 All receivables are considered short-term and due within one year. |
Prepayments and Other Receivabl
Prepayments and Other Receivables | 12 Months Ended |
Dec. 31, 2018 | |
Prepayments and Other Receivables. | |
Prepayments and Other Receivables | 10. Prepayments and Other Receivables December 31, December 31, 2018 2017 (€ in thousands) Prepayments 645 1,991 Other receivables 899 73 1,544 2,064 All receivables are considered short-term and due within one year. |
Cash and Cash Equivalents
Cash and Cash Equivalents | 12 Months Ended |
Dec. 31, 2018 | |
Cash and Cash Equivalents. | |
Cash and Cash Equivalents | 11. Cash and Cash Equivalents December 31, December 31, 2018 2017 (€ in thousands) Cash at banks 105,580 48,099 Bank deposits — — 105,580 48,099 The cash at banks is at full disposal of the Company. |
Shareholders_ Equity
Shareholders’ Equity | 12 Months Ended |
Dec. 31, 2018 | |
Shareholders’ Equity | |
Shareholders’ Equity | 12. Shareholders’ Equity (a) Share capital Number of shares 2018 Number of shares 2017 Number of shares 2016 Ordinary Ordinary Ordinary Balance at January 1 36,425,014 23,346,856 23,345,965 Issued for cash 6,612,500 8,573,975 — Issued for services 112,473 — — Exercise of share options 226,098 1,034 891 Treasury shares issued (transferred) (226,098) 4,503,149 — Balance at December 31 43,149,987 36,425,014 23,346,856 The authorized share capital of the Company amounting to € 7,200,000 consists of 90,000,000 ordinary shares and 90,000,000 preference shares with a par value of € 0.04 per share. At December 31, 2018, 43,149,987 ordinary shares were issued and fully paid in cash, of which 4,277,051 were held by the Company as treasury shares (2017: 4,503,149). In 2017, the Company has issued 976,477 shares pursuant to its current at-the-market offering program, resulting in proceeds of € 4,138,000, net of € 127,000 of offering expenses. On June 28, 2017, the Company agreed to the issuance of 1,200,000 ordinary shares to institutional investors at an issue price of $ 5.00 (€ 4.40) per share in a registered direct offering with gross proceeds of € 5,278,000. The closing of the offering was effected on July 3, 2017. Transaction costs amounted to € 414,000, resulting in net proceeds of € 4,864,000. In November 2017, the Company consummated an underwritten public offering and concurrent registered direct offering of 6,397,498 ordinary shares at an issue price of $ 3.25 (€ 2.76) per share. The gross proceeds from both offerings amounted to € 17,671,000 while the transaction costs amounted to € 988,000, resulting in net proceeds of € 16,683,000. In September 2018, the Company consummated an underwritten public offering and concurrent registered direct offering of 6,612,500 ordinary shares at an issue price of $ 15.75 per share. The gross proceeds from this offering amounted to € 89,983,000 while the transaction costs amounted to € 5,792,000, resulting in net proceeds of € 84,191,000. In November 2018, the Company issued 112,473 shares in the aggregate amount of $ 2.5 million, at $ 22.23 (€ 19.46) per share to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, an upfront payment in ordinary shares to its common stock was made to Ionis upon signing the worldwide license agreement. The Company was granted an exclusive worldwide license to QR-1123 and relevant patents. The Company will also make future milestone payments, certain of which will be made in equity and others in cash or equity at the company’s discretion, and royalties on net sales of 20% through the royalty term. On November 7, 2018, the Company filed a shelf registration statement, which permitted: (a) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 300,000,000 of its ordinary shares, warrants and/or units; and (b) as part of the $ 300,000,000, the offering, issuance and sale by us of up to a maximum aggregate offering price of $ 75,000,000 of its ordinary shares that may be issued and sold under a sales agreement with H.C. Wainwright & Co in one or more at-the-market offerings. (b) Equity settled employee benefit reserve The costs of share options for employees, members of the supervisory board and members of the management board are recognized in the income statement, together with a corresponding increase in equity during the vesting period, taking into account (deferral of) corporate income taxes. The accumulated expense of share options recognized in the income statement is shown separately in the equity category ‘equity settled employee benefit reserve’ in the ‘statement of changes in equity’. On September 25, 2017, we established a Dutch foundation named Stichting Bewaarneming Aandelen ProQR for holding shares in trust for employees, members of the Management Board and members of the Supervisory Board of the Company and its group companies who from time to time will exercise options under the Company’s equity incentive plans. (c) Translation reserve The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations. (d) Share options The Company operates an equity-settled share-based compensation plan which was introduced in 2013. Options may be granted to employees, members of the supervisory board, members of the management board and consultants. The compensation expenses included in operating costs for this plan were € 3,224,000 in 2018 (2017: € 4,024,000, 2016: € 2,454,000), of which € 2,167,000 (2017: € 2,059,000, 2016: € 1,480,000) was recorded in general and administrative costs and € 1,057,000 (2017: € 1,965,000, 2016: € 974,000) was recorded in research and development costs based on employee allocation. Options granted under this stock option plan are exercisable once vested. Any vesting schedule may be attached to the granted options, however the typical vesting period is four years (25% after every year). The options expire ten years after date of grant. Options granted under the stock option plan are granted at exercise prices which equal the fair value of the ordinary shares of the Company at the date of the grant. The Company accounts for its employee stock options under the fair value method. The fair value of the options is estimated at the date of grant using the Black-Scholes option-pricing model, with on average the following assumptions: Options granted Options granted Options granted in 2018 in 2017 in 2016 Risk-free interest rate 2.223 % 1.913 % 1.467 % Expected dividend yield — % — % — % Expected volatility 80.9 % 88.7 % 86.3 % Expected life in years 5 years 5 years 5 years The resulting weighted average grant date fair value of the options amounted to € 2.02 in 2018 (2017: € 3.21, 2016: € 3.72). The stock options granted have a 10 year life following the grant date and are assumed to be exercised five years from date of grant for all awards. Movements in the number of options outstanding and their related weighted average exercise prices are as follows: 2018 2017 2016 Number of Average Number of Average Number of Average options exercise price options exercise price options exercise price Balance at January 1 3,331,875 € 4.78 2,205,989 € 4.88 1,108,935 € 4.19 Granted 1,570,366 € 3.11 1,199,447 € 4.63 1,214,126 € 5.49 Forfeited (142,467) € 4.29 (72,527) € 5.56 (116,181) € 4.64 Exercised (226,098) € 4.02 (1,034) € 3.54 (891) € 2.38 Expired (22,164) 6 — — — — Balance at December 31 4,511,512 € 4.24 3,331,875 € 4.78 2,205,989 € 4.88 Exercisable at December 31 1,683,731 1,148,893 615,246 The options outstanding at December 31, 2018 had an exercise price in the range of € 1.11 to € 20.34 (2017: € 1.11 to € 20.34, 2016: € 1.11 to € 20.34) and a weighted-average contractual life of 7.6 years (2017: 7.9 years, 2016: 8.3 years). The weighted-average share price at the date of exercise for share options exercised in 2018 was € 15.36 (2017: € 4.32, 2016: € 4.23). Please refer to Note 23 for the options granted to key management personnel. |
Non-current liabilities
Non-current liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Non-current liabilities. | |
Non-current liabilities | 13. Non-current liabilities (a) Borrowings December 31, December 31, 2018 2017 (€ in thousands) Innovation credit 5,164 4,899 Convertible loans 1,871 662 Accrued interest 2,351 1,683 Total borrowings 9,386 7,244 Current portion — (1,960) 9,386 5,284 Innovation credit (“Innovatiekrediet”) On June 1, 2012, ProQR was awarded an Innovation credit by the Dutch government, through its agency RVO of the Ministry of Economic Affairs, for the Company’s cystic fibrosis program. Amounts were drawn under this facility in the course of the years 2013 through 2017. The credit covers 35% of the costs incurred in respect of the program up to € 5.0 million. The credit is interest-bearing at a rate of 10% per annum. Early October 2018 ProQR received a conditional waiver of the €5 million Innovation credit. The total loan of € 7.4 million including interest will be waived after 3 years if certain conditions are met. The conditions are reviewed by RVO on an annual basis. On December 10, 2018 ProQR was awarded an Innovation credit by the Dutch government, through its agency RVO of the Ministry of Economic Affairs, for the QR-110 program. Amounts will be drawn under this facility from 2018 through 2021. The credit of € 4.7 million through December 31, 2021 will be used to conduct the Phase 2/3 clinical study and efforts to obtain regulatory and ethical market approval (NDA/MAA) of QR-110 for LCA10, of which €163,000 has been received in 2018. The credit, including accrued interest of 10% per annum, is repayable depending on obtaining market approval. The credit covers 35% of the costs incurred in respect of the program up to € 4.7 million. The assets which are co-financed with the granted innovation credits are subject to a right of pledge for the benefit of RVO. Convertible loans Convertible loans were issued to Amylon Therapeutics B.V. in 2017 and 2018 and are interest-bearing at an average rate of 8% per annum. They are convertible into a variable number of ordinary shares within 36 months at the option of the holder or the Company in case financing criteria are met. Any unconverted loans become payable on demand after 24 – 36 months in equal quarterly terms. In March 2018, we entered into a convertible loan (the “Loan”), pursuant to which we borrowed an aggregate of €260,000 from the lender. The loan bears interest at a rate of 3% per annum. The outstanding principal and interest under the Loan is convertible into our ordinary shares upon the first to occur of the following events, at the election of the lender for (i) or (ii): (i) our public announcement of a strategic business partnership aimed at joint development of, or development by the partner of, our Huntington’s disease program, in which case the lender may convert the outstanding Loan amount into our ordinary shares at the then-prevailing trading price less a 25% discount; (ii) our public announcement of our decision to independently develop our Huntington’s disease program in the future, in which case the lender may convert the outstanding Loan amount into our ordinary shares at the then-prevailing trading price; or, (iii) on or around March 30, 2020 at the then-prevailing trading price plus a 25% premium. In no event are we required, nor are we permitted, to issue ordinary shares in an amount that exceeds 0.5% of the total number of ordinary shares outstanding immediately prior to the entry into the Loan. The Loan agreement restricts the lender’s ability to transfer the Loan, and prohibits the lender from entering into or engaging in any hedge, swap, short sale, derivative transaction or other agreement or arrangement that transfers any ownership of, or interests in, the Loan or our ordinary shares issued or issuable upon conversion of the Loan. The Loan and the ordinary shares issuable upon conversion of the Loan were issued in reliance on a private placement exemption from registration under the Securities Act of 1933, as amended. |
Current Liabilities
Current Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Current Liabilities. | |
Current Liabilities | 14. Current Liabilities December 31, December 31, 2018 2017 (€ in thousands) Borrowings — 1,960 Trade payables 135 546 Social securities and other taxes — 1,019 Pension premiums 7 — Deferred income 545 347 Accrued expenses and other liabilities 7,473 4,622 8,160 8,494 At December 31, 2018, current liabilities included deferred income resulting from funds received for one of our research and innovation programs. |
Other income
Other income | 12 Months Ended |
Dec. 31, 2018 | |
Other income | |
Other income | 15. Other income 2018 2017 2016 (€ in thousands) Grant income 5,378 870 1,632 Rental income from property subleases 174 625 196 Other income 209 — — 5,761 1,495 1,828 Other income is incidental by nature. In 2015, the European Commission (EC) through its Horizon 2020 program awarded us and our academic partners a grant of € 6 million to support the clinical development of eluforsen (ProQR: € 4.6 million). Horizon 2020 is one of the largest research and innovation programs in the European Union with nearly € 80 billion in available funding for qualified projects from 2014 to 2020. This program has ended at December 31, 2017 and the final amount of € 1.3 million has been recognized as other income in 2018. On February 9, 2018, the Company entered into a partnership agreement with Foundation Fighting Blindness (FFB), under which FFB has agreed to provide funding of $ 7.5 million for the preclinical and clinical development of QR‑421a for Usher syndrome type 2A targeting mutations in exon 13. In 2018 € 2.5 million has been recognized as other income. On June 5, 2018, the Company entered into a partnership agreement with EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF) under which EBRP and EBMRF have agreed to provide funding of $ 5.0 million for the clinical development of QR‑313 for Dystrophic Epidermolysis Bullosa targeting mutations in exon 73. In 2018 € 1.3 million has been recognized as other income. Grants are recognized in other income in the same period in which the related R&D costs are recognized. |
Research and Development Costs
Research and Development Costs | 12 Months Ended |
Dec. 31, 2018 | |
Research and Development Costs | |
Research and Development Costs | 16. Research and Development Costs Research and development costs amounted to € 29,514,000 in 2018 (2017: € 31,153,000,2016: € 31,923,000) and comprise allocated employee costs, the costs of materials and laboratory consumables, the costs of external studies including, amongst others, clinical studies and toxicology studies and external research, license- and IP-costs and allocated other costs. |
Employee Benefits
Employee Benefits | 12 Months Ended |
Dec. 31, 2018 | |
Employee Benefits | |
Employee Benefits | 17. Employee Benefits 2018 2017 2016 (€ in thousands) Wages and salaries 11,558 11,855 10,184 Social security costs 1,346 1,285 1,093 Pension costs — defined contribution plans 868 860 764 Equity-settled share based payments 3,224 4,024 2,454 16,996 18,024 14,495 Average number of employees for the period 127.7 139.9 133.4 Employees per activity at December 31 (converted to FTE): December 31, 2018 December 31, 2017 December 31, 2016 Research and Development 89.2 96.2 100.4 General and Administrative 29.6 34.0 32.9 Total number of employees at December 31 (converted to FTE) 118.8 130.2 133.3 Of all employees 112.8 FTE are employed in the Netherlands (2017: 125.2 FTE). Included in the wages and salaries for 2018 is a credit of € 1,294,000 (2017: € 723,000, 2016: € 807,000) with respect to WBSO subsidies. |
Financial Income and Expense
Financial Income and Expense | 12 Months Ended |
Dec. 31, 2018 | |
Financial Income and Expense | |
Financial Income and Expense | 18. Financial Income and Expense 2018 2017 2016 (€ in thousands) Interest income: Current accounts and deposits 189 90 270 Interest costs: Interest on loans and borrowings (810) (596) (538) Foreign exchange result: Net foreign exchange benefit/(loss) (171) (2,669) 738 (792) (3,175) 470 |
Income Taxes
Income Taxes | 12 Months Ended |
Dec. 31, 2018 | |
Income Taxes | |
Income Taxes | 19. Income Taxes The calculation of the tax charge is as follows: 2018 2017 2016 (€ in thousands) Income tax based on domestic rate 9,106 10,918 9,776 Tax effect of: Non-deductible expenses (818) (634) (622) Deductible expenses 1,448 — — Tax incentives — — (46) Current year losses for which no deferred tax asset was recognized (9,710) (10,257) (9,045) Change in unrecognized deductible temporary differences (25) (25) (63) Income tax charge 1 2 — Effective tax rate — % — % — % Due to the operating losses incurred since inception the Company has no tax provisions as of the balance sheet date. Furthermore, no significant temporary differences exist between accounting and tax results. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company has not yet recognized any deferred tax asset related to operating losses. As per December 31, 2018, the Company has a total amount of € 162.6 million (2017: € 123.9 million, 2016: € 82.9 million) tax loss carry-forwards available for offset against future taxable profits. According to current tax regulations the first amount of the tax loss carry-forwards will expire in 2021. |
Earnings Per Share
Earnings Per Share | 12 Months Ended |
Dec. 31, 2018 | |
Earnings Per Share | |
Earnings Per Share | 20. Earnings Per Share (a) Basic and diluted earnings per share Basic earnings per share are calculated by dividing the result attributable to equity holders of the Company by the weighted average number of shares outstanding during the year. 2018 2017 2016 Result attributable to equity holders of the Company (€ in thousands) (36,894) (43,637) (39,103) Weighted average number of shares outstanding 34,052,520 25,374,807 23,346,507 Basic (and diluted) earnings per share (€ per share) € (1.08) € (1.72) € (1.67) (b) Diluted earnings per share For the periods included in these financial statements, the share options are not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. (c) Dividends per share The Company did not declare dividends for any of the years presented in these financial statements. |
Operational Leases
Operational Leases | 12 Months Ended |
Dec. 31, 2018 | |
Operational Leases | |
Operational Leases | 21. Operational Leases Since 2012, the Company is domiciled in Leiden, the Netherlands, where it currently has entered into rental agreements for laboratory space and offices and since late 2018 in Cambridge, Massachusetts, USA. We lease facilities of approximately 2,960 square meters in total, located at Zernikedreef in Leiden, the Netherlands, where our headquarters and our laboratories are located. The lease for this facility terminates on December 31, 2020, and subject to the provisions of the lease, may then be renewed for subsequent 5 year terms. In May 2018, we entered into an agreement to lease additional office space in the US, at CIC Cambridge. Per January 2019, we rent an office of approximately 60 square meters, located at 245 Main Street, Cambridge, MA 02142. We believe that our existing facilities are adequate to meet current needs and that suitable alternative spaces will be available in the future on commercially reasonable terms. The lease expenditure charged to the income statement in 2018 amounts to € 1,813,000 (2017: € 2,103,000, 2016: € 1,849,000). The future aggregate minimum lease payments under non-cancellable operating leases are as follows: December 31, 2018 December 31, 2017 December 31, 2016 (€ in thousands) Less than 1 year 1,233 1,607 1,775 Between 1 and 5 years 1,233 3,312 5,508 More than 5 years — — — Total 2,466 4,919 7,283 The Company leased out a part of its office in the U.S. and the Netherlands during 2017 and early 2018. In 2018, total sublease income amounted to €174,000 (2017: € 625,000, 2016: €196,000), which is recorded in other income. At 31 December, the future minimum lease payments under non-cancellable leases are receivable as follows: December 31, 2018 December 31, 2017 December 31, 2016 (€ in thousands) Less than 1 year 174 463 Between 1 and 5 years — — — More than 5 years — — — Total — 174 463 |
Commitments and Contingencies
Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2018 | |
Commitments and Contingencies | |
Commitments and Contingencies | 22. Commitments and Contingencies (a) Claims There are no claims known to management related to the activities of the Company. (b) Patent license agreements On October 26, 2018, we and Ionis Pharmaceuticals, Inc. entered into a License Agreement, pursuant to which Ionis granted an exclusive, worldwide, royalty-bearing license to us to develop and commercialize certain pharmaceutical products, including the product designated by Ionis as IONIS-RHO-2.5Rx, which has been re-designated by us as QR-1123, for the prevention or treatment of retinitis pigmentosa in humans, including patient screening. Ionis also granted to the Company certain sub-license rights. Under the License Agreement, we are required to make an upfront payment of an aggregate of up to $ 6.0 million in installments, and certain payments up to an aggregate of $ 20.0 million upon the satisfaction of certain development and sales milestones. In addition, Ionis is entitled to royalty payments in the double digits of aggregate annual net sales, subject to minimum sales in certain circumstances, and subject to reduced rates in certain circumstances. The royalty term lasts on a product-by-product and country-by-country basis, until the later of the expiration of the patent rights licensed to us and the expiration of regulatory-based exclusivity for such product in such country. The License Agreement may also be terminated by either party based upon certain uncured material breach by, or insolvency of, the other party, or by us at any time with advanced notice. In connection with the upfront payments and development milestone payments, we also simultaneously entered into a Stock Purchase Agreement with Ionis, pursuant to which we agreed to issue an aggregate of $ 2.5 million of ordinary shares to satisfy the first installment upfront payment, and the remaining installment of the upfront payment in ordinary shares determined upon the due date of such installment. In addition, the Stock Purchase Agreement provides for the ability for us, at our discretion, to pay the development milestone payments in ordinary shares when such payments are due. We may not issue ordinary shares to Ionis to the extent that such issuance would result in Ionis owning in excess of 18.5% of our issued and outstanding shares, nor may we issue ordinary shares if such issuance, together with previous issuances under the Stock Purchase Agreement, would exceed 19.9% of our outstanding ordinary shares as of the date of the execution of the Stock Purchase Agreement. Under these circumstances, we are required to pay the remainder of the upfront and/or development milestone payments in cash. In addition, in connection with the Stock Purchase Agreement, we also entered into an Investor Agreement with Ionis, pursuant to which we agreed to register for resale the ordinary shares issued by us under the Stock Purchase Agreement, under the circumstances described in the Investor Agreement. The Investor Agreement also contains customary covenants related to our registration of such shares, preparation of filings in connection therewith and indemnification of Ionis. The Investor Agreement also contains lockup provisions prohibiting the disposition of our ordinary shares issued under the Stock Purchase Agreement for a period of 12 months from the applicable issuance date, as well as voting provisions requiring Ionis to vote its ordinary shares in accordance with the recommendations of our board of directors, in each case subject to certain exceptions In April 2014 the Company entered into a Patent License Agreement with Radboud University Medical Center, or Radboud in the field of antisense oligonucleotide-based therapy for Leber’s Congenital Amaurosis, or LCA. Under the terms of this license agreement, the Company has an exclusive, sublicensable, world-wide royalty-bearing license under certain Radboud patent rights to develop, make, have made, use, sell offer for sale and import of certain licensed products of Radboud for use in all prophylactic and therapeutic uses in the field of LCA. Pursuant to the terms of the license agreement, the Company is obligated to pay Radboud net-sales-related royalties which shall be determined on a product-by-product and country-by-country basis. If the Company required to pay any third party royalties, it may deduct that amount from that which is owed to Radboud. Radboud shall provide human resources, materials, facilities and equipment that are necessary for preclinical and clinical trials and if the Company does not purchase such trial facilities from Radboud, it is required to pay an increased net-sales-related royalty. In the Company’s sole discretion, it may elect to convert the obligation to pay net-sales-related royalties into one of the two lump-sum royalty options depending on whether the Company elects to convert prior to or after regulatory approval has been filed. The license agreement will remain in effect until the date on which all patent applications and all granted patents ensuing from such applications have expired or is terminated earlier in accordance with the agreement. Either party may terminate the agreement if the other party is in default of a material obligation under the agreement which has not been cured within 30 days of notice of such default. Either party may also terminate the agreement if the other party declares bankruptcy, dissolves, liquidates or the like. Radboud may also terminate the agreement if the Company does not pay any amount owed under the agreement and such payment remains overdue for at least 30 days after receiving notice from Radboud of the amount due. In June 2015, we entered into another license agreement with Radboud. Under the terms of this license agreement, the Company has an exclusive, sublicensable, world-wide royalty-bearing license under certain Radboud patent rights to develop, make, have made, use, sell offer for sale and import of certain licensed products of Radboud for use in all prophylactic and therapeutic uses in the field of Usher syndrome. Pursuant to the terms of the license agreement, the Company is obligated to pay Radboud net-sales-related royalties which shall be determined on a product-by-product and country-by-country basis. If the Company is required to pay any third party royalties, it may deduct that amount from that which is owed to Radboud. Radboud shall provide human resources, materials, facilities and equipment that are necessary for preclinical and clinical trials and if the Company does not purchase such trial facilities from Radboud, it is required to pay an increased net-sales-related royalty. In the Company’s sole discretion, it may elect to convert the obligation to pay net-sales-related royalties into one of the two lump-sum royalty options depending on whether it elects to convert prior to or after regulatory approval has been filed. The license agreement will remain in effect until the date on which all patent applications and all granted patents ensuing from such applications have expired or is terminated earlier in accordance with the agreement. Either party may terminate the agreement if the other party is in default of a material obligation under the agreement which has not been cured within 30 days of notice of such default. Either party may also terminate the agreement if the other party declares bankruptcy, dissolves, liquidates or the like. Radboud may also terminate the agreement if the Company does not pay any amount owed under the agreement and such payment remains overdue for at least 30 days after receiving notice from Radboud of the amount due. In January 2018, the Company entered into a license agreement with Inserm Transfert SA and Assistance-Publique-Hôpiteaux de Paris. Under the terms of the agreement, the Company has a world-wide, exclusive, royalty-bearing license under patent rights belonging to Inserm Transfert SA and other co-owners to develop, have developed, make, have made, use, have used and sell, have sold or otherwise distribute certain licensed products related to antisense oligonucleotides for treating LCA and method of treatment claims relating to modulation of the splicing of the CEP290 gene product. The Company has the right to grant sublicenses to third parties subject to certain limitations such as the sublicensee’s activities do not conflict with the public order or ethical obligations of Inserm Transfert SA or any co-owner and do not tarnish the image of Inserm Transfert SA or any co-owner. In partial consideration of the rights and licenses granted by the license agreement, the Company is required to make payments upon the completion of certain milestones: completion of a clinical trial more advanced than First in Man, such as a phase IIb; and the first marketing authorization or any foreign equivalent for a first product. In further consideration of the rights and license granted under the agreement, the Company shall pay to Inserm Transfert SA a running royalty on net sales of products sold by us or our sublicensee. Unless terminated earlier pursuant to termination provisions of Agreement, the license agreement will remain in effect on a country-by-country basis, until the later to occur of the following events (i) the invalidation or expiration of the last to expire or to be invalidated patent rights which covers the manufacture, use or sale of the product in said country or until the expiration of the exclusive commercialization right granted by a regulatory agency to a product as an orphan drug or (ii) five years after the first commercial sale of a product in the country in which the product is sold. The agreement may be terminated by either party in the event of an uncured breach by the non-breaching party. Inserm Transfert SA may terminate the agreement if we become the subject of voluntary or involuntary winding-up proceedings or judicial recovery, if the Company or its sublicensees interrupt development activities for at least one year, if the Company or its sublicensees interrupt commercialization for more than twelve months after the first commercialization in a country, if the Company does not commercialize a product within two years following our obtaining of marketing approval in a country, or if the Company or our sublicensees do not put a product into commercial use and do not keep products reasonably available to the public within twelve years of the effective date of the agreement. In January 2016, the Company entered into an agreement with Leiden University Medical Center, or LUMC, which gives us a world-wide, exclusive, royalty-bearing license in the field of amyloid beta related diseases, notably Alzheimer’s disease and HCHWA-D, under certain patent rights of LUMC regarding antisense oligonucleotide based therapies. This license agreement contains certain diligence obligations for the Company coupled to milestone payments and complements the Company’s intellectual property relating to its CNS program. On September 12, 2017, this program was transferred to Amylon Therapeutics B.V., in which the Company maintains a majority ownership. In January 2017, the Company entered into an agreement with LUMC, which gives us a world-wide, exclusive, royalty-bearing license in the field of Huntington’s disease, under certain patent rights of LUMC regarding antisense oligonucleotide based therapies. This license agreement contains certain diligence obligations for the Company coupled to milestone payments and complements the Company’s intellectual property relating to the HD program. In 2012, the Company and the General Hospital Corporation (MGH) have entered into a Patent License Agreement for the Company’s CF program pursuant to which the Company may have certain royalty and milestone obligations. The Company is also obligated to pay MGH up to $ 700,000 (€ 611,000) in milestone payments upon the achievement of certain development and regulatory milestones and, beginning after its first commercial sale of a product covered by the licensed patent rights, a $ 10,000 (€ 9,000) annual license fee which is creditable against royalties due to MGH in the same calendar year. In addition, the Company is obligated to pay MGH 2% of any net sales by the Company, its affiliates or sublicensees on licensed products made or sold in the United States, as well as a low double-digit percentage of any payments the Company may receive from any sublicensee anywhere in the world. (c) Clinical support agreements In August 2014, the Company entered into an agreement with Cystic Fibrosis Foundation Therapeutics, Inc., or CFFT, a subsidiary of the Cystic Fibrosis Foundation, pursuant to which CFFT agreed to provide the Company with up to $ 3 million (€ 2.6 million) to support the clinical development of eluforsen. Pursuant to the terms of the agreement, the Company is obligated to make a one-time milestone payment to CFFT of up to approximately $ 16 million (€ 14 million), payable in three equal annual installments following the first commercial sale of eluforsen, the first of which is due within 90 days following the first commercial sale. The Company is also obligated to make a one-time milestone payment to CFFT of up to $ 3 million (€ 2.6 million) if net sales of eluforsen exceed $ 500 million (€ 437 million) in a calendar year. Lastly, the Company is obligated to make a payment to CFFT of up to approximately $ 6 million (€ 5 million) if it transfers, sells or licenses eluforsen other than for certain clinical or development purposes, or if the Company enters into a change of control transaction prior to commercialization. However, the payment in the previous sentence may be set-off against the $ 16 million milestone payment. Either CFFT or the Company may terminate the agreement for cause, which includes the Company’s material failure to achieve certain commercialization and development milestones. The Company’s payment obligations survive the termination of the agreement. On February 9, 2018, the Company entered into an agreement with Foundation Fighting Blindness (FFB), under which FFB will provide funding of $ 7.5 million (€ 6.6 million) to advance QR‑421a into the clinic and will receive future milestone payments. Pursuant to the terms of the agreement, the Company is obligated to make a one-time milestone payment to FFB of up to approximately $ 37.5 million (€ 32.8 million), payable in four equal annual installments following the first commercial sale of QR‑421a, the first of which is due within 60 days following the first commercial sale. The Company is also obligated to make a payment to FFB of up to approximately $ 15 million (€ 13.1 million) if it transfers, sells or licenses QR‑421a other than for certain clinical or development purposes, or if the Company enters into a change of control transaction. However, the payment in the previous sentence may be set-off against the $ 37.5 million milestone payment. Either FFB or the Company may terminate the agreement for cause, which includes the Company’s material failure to achieve certain commercialization and development milestones. The Company’s payment obligations survive the termination of the agreement. On June 5, 2018, the Company entered into a partnership agreement with EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF) under which EBRP and EBMRF have agreed to provide funding of $ 5.0 million for the clinical development of QR-313 for Dystrophic Epidermolysis Bullosa targeting mutations in exon 73. Pursuant to the terms of the agreement, the Company shall, during the period starting upon completing a Successful Clinical Study, pay EBRP the total Actual Award in 12 equal semi-annual installments of the Actual Award made by EBRP. ProQR shall have the option, at its discretion, to pay the amount for each installment in ProQR Therapeutics N.V. shares at the price of market close on the payment due date. In addition to the payment in subparagraph (a) above, ProQR shall pay a return on investment to EBRP in an amount equal of 1.36 times the Actual Award at the first anniversary of First Commercial Sale; 1.36 times the Actual Award at the second anniversary of First Commercial Sale; 1.36 times the Actual Award at the third anniversary of First Commercial Sale; and 1.0 times the Actual Award when aggregate Net Sales of the Product exceed $ 100 million. In the event of a License Transaction by ProQR or a Change of Control Transaction (collectively a “Disposition Transaction”): (i) ProQR shall pay to EBRP 33.3 percent of any consideration received by ProQR in connection with such transaction (whether up front or in subsequent milestone or other payments and whether in cash or other property) not to exceed four (4) times the amount of the Actual Award (the “Disposition Payment”), provided that (i) the amount of the actual total payment previously made by ProQR under Section 2(a) shall be deducted from the amount of the “Disposition Payment”. (d) Research and development commitments The Company has research and development commitments, mainly with CRO’s, amounting to € 8,114,000 at December 31, 2018 (2017: € 7,704,000). Of these obligations an amount of € 5,807,000 is due in 2019, the remainder is due in 1 to 5 years. |
Related-Party Transactions
Related-Party Transactions | 12 Months Ended |
Dec. 31, 2018 | |
Related-Party Transactions | |
Related-Party Transactions | 23. Related-Party Transactions Details of transactions between the Company and related parties are disclosed below. (a) Compensation of the Supervisory Board The remuneration of the supervisory board members in 2018 is set out in the table below: 2018 Short term Post-employment Share-based employee benefits benefits payment Total (€ in thousands) Mr. Dinko Valerio 36 — 69 105 Mr. Antoine Papiernik 72 — — 72 Ms. Alison Lawton 31 — 75 106 Mr. Paul Baart 80 — — 80 Mr. James Shannon 33 — 73 106 252 — 217 469 The remuneration of the supervisory board members in 2017 is set out in the table below: 2017 Short term Post employment Share-based employee benefits benefits payment Total (€ in thousands) Mr. Dinko Valerio 36 — 87 123 Mr. Henri Termeer 28 — 160 188 Mr. Antoine Papiernik 76 — — 76 Ms. Alison Lawton 31 — 99 130 Mr. Paul Baart 84 — — 84 Mr. James Shannon 33 — 92 125 288 — 438 726 The 2016 remuneration is set out in the table below: 2016 Short term Post employment Share-based employee benefits benefits payment Total (€ in thousands) Mr. Dinko Valerio 36 — 52 88 Mr. Henri Termeer 31 — 51 82 Mr. Antoine Papiernik 78 — — 78 Ms. Alison Lawton 31 — 74 105 Mr. Paul Baart 82 — — 82 Mr. James Shannon 29 — 27 56 287 — 204 491 As at December 31, 2018: · Mr. Valerio holds 1,043,420 ordinary shares in the Company, as well as 115,925 options. These options vest in four annual equal tranches of 25% starting for the first time as of the first anniversary of the date of grant. In 2016, Mr. Valerio was granted 23,989 options under the Option Plan to acquire depositary receipts issued for ordinary shares at an exercise price of € 6.08 per option. In 2017, Mr. Valerio was granted 32,164 options at an average exercise price of € 4.65 per option. In 2018, Mr. Valerio was granted 27,500 options at an average exercise price of € 2.74 per option. On September 12, 2017, Mr. Valerio provided a convertible loan to Amylon Therapeutics B.V. This loan is interest-bearing at an average rate of 8% per annum and is convertible into a variable number of ordinary shares within 36 months at the option of the holder or the Company in case financing criteria are met. Any unconverted loans become payable on demand after 24 months in equal quarterly terms. · Mr. Antoine Papiernik does not hold any shares or options in the Company. As a managing partner of Sofinnova Partners SAS, the management company of Sofinnova Capital VII FCPR, holder of 2,764,194 ordinary shares, Mr. Papiernik may be deemed to have share voting and investment power with respect to such shares. · Ms. Lawton holds 96,473 options. In 2016, Ms. Lawton was granted 23,989 options under the Option Plan to acquire depositary receipts issued for ordinary shares at with an exercise price of € 6.08 per option. In 2017, Ms. Lawton was granted 32,164 options with an average exercise price of € 4.65 per option. In 2018, Ms. Lawton was granted 27,500 options with an average exercise price of € 2.74 per option. Under these option grants options vest in four annual equal tranches of 25% starting for the first time as of the first anniversary of the date of grant. · Mr. Paul Baart does not hold any shares or options in the Company. · Mr. James Shannon holds 61,538 ordinary shares in the Company and 92,733 options. In 2016, Mr. Shannon was granted 33,069 options under the Option Plan to acquire depositary receipts issued for ordinary shares at an exercise price of € 4.32 per option. In 2017, Mr. Shannon was granted 32,164 options at an exercise price of € 4.65 per option. In 2018, Mr. Shannon was granted 27,500 options at an exercise price of € 2.74 per option. Under these option grants options vest in four annual equal tranches of 25% starting for the first time as of the first anniversary of the date of grant. (b) Compensation of key management Our management board is supported by our officers, or senior management. The total remuneration of the management board and senior management in 2018 amounted to € 5,481,000 with the details set out in the table below: 2018 Short term Post employee employment Share-based benefits benefits payment Total (€ in thousands) Mr. D.A. de Boer 1 726 9 668 1,403 Mr. R.K. Beukema 2 809 16 464 1,289 Management Board 1,535 25 1,132 2,692 Senior Management 1,726 64 999 2,789 3,261 89 2,131 5,481 1 Short term employee benefits includes a bonus for Mr. Daniel de Boer, of € 281,000 based on goals realised in 2018. 2 Short term employee benefits includes a bonus for Mr. René Beukema, of € 134,000 based on goals realised in 2018 and a severance payment of € 324,000. The total remuneration of the management board and senior management in 2017 amounted to € 5,096,000 with the details set out in the table below: 2017 Short term Post employee employment Share-based benefits benefits payment Total (€ in thousands) Mr. D.A. de Boer 1 570 8 622 1,200 Mr. R.K. Beukema 2 411 15 261 687 Management Board 981 23 883 1,887 Senior Management 1,719 66 1,424 3,209 2,700 89 2,307 5,096 1 Short term employee benefits includes a bonus for Mr. Daniel de Boer of € 217,000 based on goals realised in 2017. 2 Short term employee benefits includes a bonus for Mr. René Beukema of € 113,000 based on goals realised in 2017. The total remuneration of the management board and senior management in 2016 amounted to € 3,038,000 with the details set out in the table below: 2016 Short term Post employee employment Share-based benefits benefits payment Total (€ in thousands) Mr. D.A. de Boer 1 429 7 391 827 Mr. R.K. Beukema 2 346 13 165 524 Management Board 775 20 556 1,351 Senior Management 1,020 48 619 1,687 1,795 68 1,175 3,038 1 Short term employee benefits includes a bonus for Mr. Daniel de Boer of € 131,000 based on goals realised in 2016. 2 Short term employee benefits includes a bonus for Mr. René Beukema of € 76,000 based on goals realised in 2016. As at December 31, 2018: · Mr. de Boer holds 705,309 ordinary shares in the Company as well as 828,623 options. In 2016, Mr. de Boer was awarded 129,727 options to acquire ordinary shares at an exercise price of € 6.64 per option. In 2017, Mr. de Boer was awarded 239,717 options at an exercise price of € 4.65 per option. In 2018, Mr. de Boer was awarded 379,285 options at an exercise price of € 2.74 per option. These options vest over four years in equal annual installments and had a remaining weighted-average contractual life of 8.1 years at December 31, 2018. · Mr. Beukema holds 346,239 ordinary shares in the Company as well as 440,013 options. In 2016, Mr. Beukema was awarded 50,608 options to acquire ordinary shares at an exercise price of € 6.64 per option. In 2017, Mr. Beukema was awarded 101,408 options at an exercise price of € 4.65 per option. In 2018, Mr. Beukema was awarded 140,932 options at an exercise price of € 2.74 per option. These options vest over four years in equal annual installments and had a remaining weighted-average contractual life of 7.2 years at December 31, 2018. Mr. Beukema left the Company January 1, 2019. ProQR does not grant any loans, advanced payments and guarantees to members of the Management and Supervisory Board. |
Auditor fees
Auditor fees | 12 Months Ended |
Dec. 31, 2018 | |
Auditor fees | |
Auditor fees | 24. Auditor fees The fees for services provided by our external auditor, Deloitte Accountants B.V., are specified below for each of the financial years indicated: 2018 2017 2016 (€ in thousands) Audit fees 181 175 165 Audit-related fees 261 140 39 Tax fees — — — All other fees — — — 442 315 204 Audit fees Consist of aggregate fees for professional services provided in connection with the annual audit of our financial statements, procedures on our quarterly financial statements, consultations on accounting matters directly related to the audit, and comfort letters, consents and assistance with and review of documents filed with the SEC. |
Subsequent events
Subsequent events | 12 Months Ended |
Dec. 31, 2018 | |
Subsequent events | |
Subsequent events | 25. Subsequent events On March 26, 2019, the Company announced the strategic spin out of the Dystrophic Epidermolysis Bullosa (DEB) activities into the newly formed company, Wings Therapeutics. This company is formed and financed by EB Research Partnership (EBRP), the largest global non-profit dedicating to treating and curing EB. Wings Therapeutics will focus on developing therapies for DEB and continue to conduct clinical trials with QR-313 in exon 73 as well as progress other RNA molecules that are designed for other mutations that cause DEB. ProQR has a minority stake in Wings Therapeutics and will be eligible for milestone and royalty rights to commercial products. The financial impact on the Company is estimated to be immaterial. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Significant Accounting Policies | |
Basis of consolidation | (a) Basis of consolidation (i) Subsidiaries Subsidiaries are entities controlled by the Group. The Group controls an entity when it has power over the entity, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The Group reassesses whether or not it controls an entity if facts and circumstances indicate that there are changes to one or more of these elements. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. (ii) Non-controlling interests (“NCI”) NCI are measured at their proportionate share of the acquiree's identifiable net assets at the acquisition date. Changes in the Group's interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. (iii) Loss of control When the Group loses control over a subsidiary, it derecognizes the assets and liabilities of the subsidiary, and any non-controlling interests and other components of equity. Any resulting gain or loss is recognized in profit or loss. Any interest retained in the former subsidiary is measured at fair value when control is lost. (iv) Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated. Unrealized gains arising from transactions with equity-accounted investees are eliminated against the investment to the extent of the Group’s interest in the investee. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment. |
Classes of financial instruments | (b) Classes of financial instruments Financial instruments are both primary financial instruments, such as receivables and payables, and financial derivatives. For primary financial instruments, reference is made to the treatment per the corresponding balance sheet item. Financial derivatives are valued at fair value. Upon first recognition, financial derivatives are recognized at fair value and then revalued as at balance sheet date. |
Foreign currencies | (c) Foreign currencies (i) Foreign currency transactions Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are translated into the functional currency at the exchange rate when the fair value was determined. Foreign currency differences are generally recognized in profit or loss. Non-monetary items that are measured based on historical cost in a foreign currency are not translated. (ii) Foreign operations The assets and liabilities of foreign operations are translated into euro at exchange rates at the reporting date. The income and expenses of foreign operations are translated into euros at the exchange rates at the dates of the transactions. Foreign currency differences are recognized in OCI and accumulated in the translation reserve, except to the extent that the translation difference is allocated to NCI. |
Recognition of other income | (d) Recognition of other income Other income includes amounts earned from third parties and are recognized when earned in accordance with the substance and under the terms of the related agreements and when it is probable that the economic benefits associated with the transaction will flow to the entity and the amount of the income can be measured reliably. The grants are recognized in other income on a systematic basis over the period the Company recognizes as expenses the related costs for which the grants are expected to compensate. |
Government grants — WBSO | (e) Government grants — WBSO The WBSO (“afdrachtvermindering speur- en ontwikkelingswerk”) is a Dutch fiscal facility that provides subsidies to companies, knowledge centers and self-employed people who perform research and development activities (as defined in the WBSO Act). Under this Act, a contribution is paid towards the labor costs of employees directly involved in research and development. The contribution is in the form of a reduction of payroll taxes and social security contributions recognized on a net basis within the labor costs. Subsidies relating to labor costs are deferred and recognized in the income statement in the period necessary to match them with the labor costs that they are intended to compensate. |
Employee benefits | (f) Employee benefits (i) Short-term employee benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. (ii) Share-based payment transactions The grant-date fair value of equity-settled share-based payment awards granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. (iii) Pension obligations The Company operates defined contribution pension plans for all employees funded through payments to insurance companies. The Company has no legal or constructive obligation to pay further contributions once the contributions have been paid. The contributions are recognized as employee benefit expense when employees have rendered the service entitling them to the contributions. Prepaid contributions are recognized as an asset to the extent that a cash refund or a reduction in the future payments is available. |
Taxation | (g) Taxation Income tax expense represents the sum of the tax currently payable and deferred tax. It is recognized in profit or loss except to the extent that it relates to a business combination, or items recognized directly in equity or in OCI. (i) Current tax The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. (ii) Deferred tax Deferred tax is recognized on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Since the Company does not expect to be profitable in the foreseeable future, its deferred tax assets are valued at nil. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. |
Intangible assets | (h) Intangible assets (i) Licenses Acquired patents have a finite useful life and are carried at cost less accumulated amortization and impairment losses. Amortization is calculated using the straight-line method to allocate the cost of patents over their estimated useful lives (generally 10 years unless a patent expires prior to that date). Amortization begins when an asset is available for its intended use. (ii) Research and development Research expenditures are recognized as expenses as incurred. Costs incurred on development projects are recognized as intangible assets as of the date that it can be established that it is probable that future economic benefits that are attributable to the asset will flow to the Company considering its commercial and technological feasibility, generally when filed for regulatory approval for commercial production, and when costs can be measured reliably. Given the current stage of the development of the Company’s products no development expenditures have yet been capitalized. Registration costs for patents are part of the expenditures for the research and development project. Therefore, registration costs for patents are expensed as incurred as long as the research and development project concerned does not yet meet the criteria for capitalization. (iii) Other intangible assets Other intangible assets, including software, that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. (iv) Amortization Amortization is calculated to write off the cost of intangible assets less their estimated residual values using the straight-line method over their estimated useful lives, and is recognized in profit or loss. The estimated useful lives for current and comparative periods are as follows: software: years; Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate. |
Property, plant and equipment | (i) Property, plant and equipment (i) Recognition and measurement Items of property, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment. Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss. (ii) Depreciation Depreciation is calculated to write off the cost of items of property, plant and equipment less their estimated residual values using the straight-line method over their estimated useful lives, and is recognized in profit or loss. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. The estimated useful lives of property, plant and equipment for current and comparative periods are as follows: leasehold improvements: 5-10 years; laboratory equipment: years; other: 3-5 years. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate |
Impairment of tangible and intangible assets | (j) Impairment of tangible and intangible assets At the end of each reporting period, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. Where a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified. Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. The recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase. |
Financial assets | (k) Financial assets All financial assets are recognized and derecognized on the trade date where the purchase or sale of a financial asset is under a contract whose terms require delivery of the financial asset within the timeframe established by the market concerned, and are initially measured at fair value and subsequently measured at amortized cost or fair value on the basis of the entity’s business model for managing the financial assets and the contractual cash flow characteristics of the financial assets. Specifically: · debt instruments that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal amount outstanding, are measured subsequently at amortised cost, and · all other debt investments and equity investments are measured subsequently at fair value through profit or loss (FVTPL). |
Contract receivables | (l) Contract receivables Contract receivables, loans and other receivables that have fixed or determinable payments that are not quoted in an active market are classified as “loans and receivables”. Loans and receivables are measured at amortized cost using the effective interest method, less any impairment. The group applies the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due. Trade receivables are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan with the group, and a failure to make contractual payments for a period of greater than 120 days past due. Impairment losses on trade receivables and contract assets are presented as net impairment losses within operating profit. Subsequent recoveries of amounts previously written off are credited against the same line item. Previous accounting policy for impairment of trade receivables In the prior year, an allowance for doubtful accounts is established when there is objective evidence that the Company will not be able to collect all amounts due according to the original terms of receivables. Significant financial difficulties of the debtor, probability that the debtor will enter into bankruptcy or financial reorganization, and default or delinquency in payments are considered indicators that the trade receivable is impaired. Loans and receivables are included in ‘current assets’, except for maturities greater than 12 months after the balance sheet date, which are classified as ‘non-current assets’. |
Cash and cash equivalents | (m) Cash and cash equivalents Cash and cash equivalents include cash on hand and all highly liquid investments with original maturities of three months or less that are convertible to a known amount of cash and bear an insignificant risk of change in value. |
Financial liabilities and equity instruments | (n) Financial liabilities and equity instruments Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangement. Equity instruments An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs. Compound financial instruments Compound financial instruments issued by the Group comprise convertible notes denominated in euro that can be converted to share capital at the option of the holder, when the number of shares to be issued is fixed and does not vary with changes in fair value. The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversion option. The equity component is recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not remeasured. Interest related to the financial liability is recognized in profit or loss. On conversion, the financial liability is reclassified to equity and no gain or loss is recognized. Other financial liabilities Other financial liabilities, including borrowings, are initially measured at fair value, net of transaction costs incurred, and are subsequently measured at amortized cost using the effective interest method, with interest expense recognized on an effective yield basis. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period. Borrowings and other financial liabilities are classified as ‘non-current liabilities,’ other than liabilities with maturities up to one year, which are classified as “current liabilities”. The Company derecognizes financial liabilities when the liability is discharged, cancelled or expired. For all financial liabilities, the fair value approximates its carrying amount. |
Leases | (o) Leases (i) Determining whether an arrangement contains a lease At inception of an arrangement, the Company determines whether such an arrangement is or contains a lease. At inception or on reassessment of an arrangement that contains a lease, the Company separates payments and other consideration required by such an arrangement into those for the lease and those for other elements on the basis of their relative fair values. If the Company concludes for a finance lease that it is impracticable to separate the payments reliably, then an asset and a liability are recognized at an amount equal to the fair value of the underlying asset. Subsequently, the liability is reduced as payments are made and an imputed finance cost on the liability is recognized using the Company’s incremental borrowing rate. (ii) Leased assets Assets held by the Company under leases that transfer to the Company substantially all of the risks and rewards of ownership are classified as finance leases. The leased assets are measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the assets are accounted for in accordance with the accounting policy applicable to that asset. Assets held under other leases are classified as operating leases and are not recognized in the Company’s statement of financial position. (iii) Lease payments Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease. Minimum lease payments made under finance leases are apportioned between the finance expense and the reduction of the outstanding liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Significant Accounting Policies | |
Estimated useful lives for current and comparative periods | software: years; |
Estimated useful lives of property, plant and equipment | leasehold improvements: 5-10 years; laboratory equipment: years; other: 3-5 years. |
Financial Risk Management (Tabl
Financial Risk Management (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Financial Risk Management | |
Schedule of undiscounted liabilities into relevant maturity groupings. | Less than Between 1 Between 2 1 year and 2 years and 5 years Over 5 years (€ in thousands) At December 31, 2018 Borrowings — 8,984 — Trade payables and other payables 8,160 — — — Total 8,160 797 8,984 — At December 31, 2017 Borrowings 1,960 980 5,981 — Trade payables and other payables 6,534 — — — Total 8,494 980 5,981 — |
Intangible Assets (Tables)
Intangible Assets (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Intangible Assets | |
Disclosure of detailed information about intangible assets | Licenses Software Total (€ in thousands) (€ in thousands) (€ in thousands) Balance at January 1, 2017 Cost 39 152 191 Accumulated amortization — (101) (101) Carrying amount 39 51 90 Additions — — — Amortization — (51) (51) Movement for the period — (51) (51) Balance at December 31, 2017 Cost 39 152 191 Accumulated amortization — (152) (152) Carrying amount 39 — 39 Additions — — — Impairment (39) — (39) Amortization — — — Movement for the period (39) — (39) Balance at December 31, 2018 Cost 39 152 191 Accumulated amortization (39) (152) (191) Carrying amount — — — |
Property, Plant and Equipment_2
Property, Plant and Equipment ('PP&E') (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Property, Plant and Equipment ('PP&E") | |
Property, Plant and Equipment ('PP&E') | Leasehold Laboratory improvements equipment Other Total (€ in thousands) (€ in thousands) (€ in thousands) (€ in thousands) Balance at January 1, 2017 Cost 1,847 1,957 1,283 5,087 Accumulated depreciation (508) (660) (481) (1,649) Carrying amount 1,339 1,297 802 3,438 Additions 9 47 26 82 Depreciation (294) (409) (312) (1,015) Transfer — — — — Disposals — — — — Movement for the period (285) (362) (286) (933) Balance at December 31, 2017 Cost 1,856 2,004 1,309 5,169 Accumulated depreciation (802) (1,069) (793) (2,664) Carrying amount 1,054 935 516 2,505 Additions 18 281 13 312 Depreciation (296) (419) (238) (953) Disposals — — — — Movement for the period (278) (138) (225) (641) Balance at December 31, 2018 Cost 1,874 2,285 1,322 5,481 Accumulated depreciation (1,098) (1,488) (1,031) (3,617) Carrying amount 776 797 291 1,864 |
Social Security and Other Tax_2
Social Security and Other Taxes (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Social Security and Other Taxes | |
Social Security and Other Taxes | December 31, December 31, 2018 2017 (€ in thousands) Value added tax 311 396 Wage tax 932 — 1,243 396 |
Prepayments and Other Receiva_2
Prepayments and Other Receivables (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Prepayments and Other Receivables. | |
Prepayments and Other Receivables | December 31, December 31, 2018 2017 (€ in thousands) Prepayments 645 1,991 Other receivables 899 73 1,544 2,064 |
Cash and Cash Equivalents (Tabl
Cash and Cash Equivalents (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Cash and Cash Equivalents. | |
Cash and Cash Equivalents | December 31, December 31, 2018 2017 (€ in thousands) Cash at banks 105,580 48,099 Bank deposits — — 105,580 48,099 |
Shareholders_ Equity (Tables)
Shareholders’ Equity (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Shareholders’ Equity | |
Schedule of Share capital | Number of shares 2018 Number of shares 2017 Number of shares 2016 Ordinary Ordinary Ordinary Balance at January 1 36,425,014 23,346,856 23,345,965 Issued for cash 6,612,500 8,573,975 — Issued for services 112,473 — — Exercise of share options 226,098 1,034 891 Treasury shares issued (transferred) (226,098) 4,503,149 — Balance at December 31 43,149,987 36,425,014 23,346,856 |
Schedule of fair value of options calculated using Black-Scholes option pricing model and weighted average assumptions utilized | Options granted Options granted Options granted in 2018 in 2017 in 2016 Risk-free interest rate 2.223 % 1.913 % 1.467 % Expected dividend yield — % — % — % Expected volatility 80.9 % 88.7 % 86.3 % Expected life in years 5 years 5 years 5 years |
Schedule of Movements in the number of options outstanding and weighted average exercise prices | 2018 2017 2016 Number of Average Number of Average Number of Average options exercise price options exercise price options exercise price Balance at January 1 3,331,875 € 4.78 2,205,989 € 4.88 1,108,935 € 4.19 Granted 1,570,366 € 3.11 1,199,447 € 4.63 1,214,126 € 5.49 Forfeited (142,467) € 4.29 (72,527) € 5.56 (116,181) € 4.64 Exercised (226,098) € 4.02 (1,034) € 3.54 (891) € 2.38 Expired (22,164) 6 — — — — Balance at December 31 4,511,512 € 4.24 3,331,875 € 4.78 2,205,989 € 4.88 Exercisable at December 31 1,683,731 1,148,893 615,246 |
Non-current liabilities (Tables
Non-current liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Non-current liabilities. | |
Borrowings | December 31, December 31, 2018 2017 (€ in thousands) Innovation credit 5,164 4,899 Convertible loans 1,871 662 Accrued interest 2,351 1,683 Total borrowings 9,386 7,244 Current portion — (1,960) 9,386 5,284 |
Current Liabilities (Tables)
Current Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Current Liabilities. | |
Current liabilities | December 31, December 31, 2018 2017 (€ in thousands) Borrowings — 1,960 Trade payables 135 546 Social securities and other taxes — 1,019 Pension premiums 7 — Deferred income 545 347 Accrued expenses and other liabilities 7,473 4,622 8,160 8,494 |
Other income (Tables)
Other income (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Other income | |
Other income | 2018 2017 2016 (€ in thousands) Grant income 5,378 870 1,632 Rental income from property subleases 174 625 196 Other income 209 — — 5,761 1,495 1,828 |
Employee Benefits (Tables)
Employee Benefits (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Employee Benefits | |
Schedule of employee benefit | 2018 2017 2016 (€ in thousands) Wages and salaries 11,558 11,855 10,184 Social security costs 1,346 1,285 1,093 Pension costs — defined contribution plans 868 860 764 Equity-settled share based payments 3,224 4,024 2,454 16,996 18,024 14,495 Average number of employees for the period 127.7 139.9 133.4 |
Schedule of employee per activity | December 31, 2018 December 31, 2017 December 31, 2016 Research and Development 89.2 96.2 100.4 General and Administrative 29.6 34.0 32.9 Total number of employees at December 31 (converted to FTE) 118.8 130.2 133.3 |
Financial Income and Expense (T
Financial Income and Expense (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Financial Income and Expense | |
Schedule of financial income and expense | 2018 2017 2016 (€ in thousands) Interest income: Current accounts and deposits 189 90 270 Interest costs: Interest on loans and borrowings (810) (596) (538) Foreign exchange result: Net foreign exchange benefit/(loss) (171) (2,669) 738 (792) (3,175) 470 |
Income Taxes (Tables)
Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Income Taxes | |
Schedule of calculation tax charge | 2018 2017 2016 (€ in thousands) Income tax based on domestic rate 9,106 10,918 9,776 Tax effect of: Non-deductible expenses (818) (634) (622) Deductible expenses 1,448 — — Tax incentives — — (46) Current year losses for which no deferred tax asset was recognized (9,710) (10,257) (9,045) Change in unrecognized deductible temporary differences (25) (25) (63) Income tax charge 1 2 — Effective tax rate — % — % — % |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Earnings Per Share | |
Schedule of basic earnings per share are calculated | 2018 2017 2016 Result attributable to equity holders of the Company (€ in thousands) (36,894) (43,637) (39,103) Weighted average number of shares outstanding 34,052,520 25,374,807 23,346,507 Basic (and diluted) earnings per share (€ per share) € (1.08) € (1.72) € (1.67) |
Operational Leases (Tables)
Operational Leases (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Operational Leases | |
Schedule of the future aggregate minimum lease payments under non-cancellable operating leases | December 31, 2018 December 31, 2017 December 31, 2016 (€ in thousands) Less than 1 year 1,233 1,607 1,775 Between 1 and 5 years 1,233 3,312 5,508 More than 5 years — — — Total 2,466 4,919 7,283 |
Schedule of the future minimum lease payments under non-cancellable leases are receivable | December 31, 2018 December 31, 2017 December 31, 2016 (€ in thousands) Less than 1 year 174 463 Between 1 and 5 years — — — More than 5 years — — — Total — 174 463 |
Related-Party Transactions (Tab
Related-Party Transactions (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Supervisory Board | |
Transactions between the Company and related parties | |
Schedule of transactions between company and related parties | The remuneration of the supervisory board members in 2018 is set out in the table below: 2018 Short term Post-employment Share-based employee benefits benefits payment Total (€ in thousands) Mr. Dinko Valerio 36 — 69 105 Mr. Antoine Papiernik 72 — — 72 Ms. Alison Lawton 31 — 75 106 Mr. Paul Baart 80 — — 80 Mr. James Shannon 33 — 73 106 252 — 217 469 The remuneration of the supervisory board members in 2017 is set out in the table below: 2017 Short term Post employment Share-based employee benefits benefits payment Total (€ in thousands) Mr. Dinko Valerio 36 — 87 123 Mr. Henri Termeer 28 — 160 188 Mr. Antoine Papiernik 76 — — 76 Ms. Alison Lawton 31 — 99 130 Mr. Paul Baart 84 — — 84 Mr. James Shannon 33 — 92 125 288 — 438 726 The 2016 remuneration is set out in the table below: 2016 Short term Post employment Share-based employee benefits benefits payment Total (€ in thousands) Mr. Dinko Valerio 36 — 52 88 Mr. Henri Termeer 31 — 51 82 Mr. Antoine Papiernik 78 — — 78 Ms. Alison Lawton 31 — 74 105 Mr. Paul Baart 82 — — 82 Mr. James Shannon 29 — 27 56 287 — 204 491 |
Key management personnel | |
Transactions between the Company and related parties | |
Schedule of transactions between company and related parties | Our management board is supported by our officers, or senior management. The total remuneration of the management board and senior management in 2018 amounted to € 5,481,000 with the details set out in the table below: 2018 Short term Post employee employment Share-based benefits benefits payment Total (€ in thousands) Mr. D.A. de Boer 1 726 9 668 1,403 Mr. R.K. Beukema 2 809 16 464 1,289 Management Board 1,535 25 1,132 2,692 Senior Management 1,726 64 999 2,789 3,261 89 2,131 5,481 1 Short term employee benefits includes a bonus for Mr. Daniel de Boer, of € 281,000 based on goals realised in 2018. 2 Short term employee benefits includes a bonus for Mr. René Beukema, of € 134,000 based on goals realised in 2018 and a severance payment of € 324,000. The total remuneration of the management board and senior management in 2017 amounted to € 5,096,000 with the details set out in the table below: 2017 Short term Post employee employment Share-based benefits benefits payment Total (€ in thousands) Mr. D.A. de Boer 1 570 8 622 1,200 Mr. R.K. Beukema 2 411 15 261 687 Management Board 981 23 883 1,887 Senior Management 1,719 66 1,424 3,209 2,700 89 2,307 5,096 1 Short term employee benefits includes a bonus for Mr. Daniel de Boer of € 217,000 based on goals realised in 2017. 2 Short term employee benefits includes a bonus for Mr. René Beukema of € 113,000 based on goals realised in 2017. The total remuneration of the management board and senior management in 2016 amounted to € 3,038,000 with the details set out in the table below: 2016 Short term Post employee employment Share-based benefits benefits payment Total (€ in thousands) Mr. D.A. de Boer 1 429 7 391 827 Mr. R.K. Beukema 2 346 13 165 524 Management Board 775 20 556 1,351 Senior Management 1,020 48 619 1,687 1,795 68 1,175 3,038 1 Short term employee benefits includes a bonus for Mr. Daniel de Boer of € 131,000 based on goals realised in 2016. 2 Short term employee benefits includes a bonus for Mr. René Beukema of € 76,000 based on goals realised in 2016. |
Auditor fees (Tables)
Auditor fees (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Auditor fees | |
Schedule of auditors remuneration for services provided | 2018 2017 2016 (€ in thousands) Audit fees 181 175 165 Audit-related fees 261 140 39 Tax fees — — — All other fees — — — 442 315 204 |
General Information (Details)
General Information (Details) | 12 Months Ended |
Dec. 31, 2018 | |
ProQR Therapeutics Holding B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics I B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics II B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics III B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics IV B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics VI B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics VII B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics VIII B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics IX B.V. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
Amylon Therapeutics B.V [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 80.00% |
Amylon Therapeutics Inc [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
ProQR Therapeutics I Inc. [Member] | |
Disclosure of subsidiaries [line items] | |
Proportion of ownership interest in subsidiary | 100.00% |
Significant Accounting Polici_4
Significant Accounting Policies - Estimated useful lives (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Impairment loss | € 0 | |
Leasehold improvements | Minimum | ||
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Estimated useful life, property, plant and equipment | 5 years | |
Leasehold improvements | Maximum | ||
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Estimated useful life, property, plant and equipment | 10 years | |
Laboratory equipment | ||
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Estimated useful life, property, plant and equipment | 5 years | |
Other | Minimum | ||
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Estimated useful life, property, plant and equipment | 3 years | |
Other | Maximum | ||
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Estimated useful life, property, plant and equipment | 5 years | |
Patents | ||
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Estimated useful life, intangibles | 10 years | |
Software | ||
Disclosure Of Detailed Information About Intangibles, Property, Plant And Equipment [Line Items] | ||
Estimated useful life, intangibles | 3 years |
New standards and interpretat_2
New standards and interpretations not yet adopted (Details) € in Millions | Dec. 31, 2018EUR (€) |
Proforma Adjustment | IFRS 16 | |
Disclosure of expected impact of initial application of new standards or interpretations [line items] | |
Lease liabilities | € 2.3 |
Financial Risk Management - Nar
Financial Risk Management - Narrative (Details) - EUR (€) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Financial Risk Management | ||
Foreign currency liability in U.S. Dollars | € 100,000 | € 700,000 |
Foreign Currency Denominated Receivables And Trade Payable Minimum Term | 30 days | |
Foreign Currency Denominated Receivables And Trade Payable Maximum Term | 45 days | |
Market risk indicator used to assess the affect on cash balances | 10.00% | |
Hypothetical Impact to Profit and Loss due to Market Risk | € 2,400,000 | 2,500,000 |
Borrowings | € 9,386,000 | € 7,244,000 |
Financial Risk Management - Und
Financial Risk Management - Undiscounted Liabilities by Maturity (Details) - EUR (€) | Dec. 31, 2018 | Dec. 31, 2017 |
Disclosure of detailed information about borrowings [line items] | ||
Borrowings | € 9,386,000 | € 7,244,000 |
Trade payables and other payables | 135,000 | 546,000 |
Less than 1 year [Member] | ||
Disclosure of detailed information about borrowings [line items] | ||
Borrowings | 1,960,000 | |
Trade payables and other payables | 8,160,000 | 6,534,000 |
Total | 8,160,000 | 8,494,000 |
Between 1 and 2 years [Member] | ||
Disclosure of detailed information about borrowings [line items] | ||
Borrowings | 797,000 | 980,000 |
Total | 797,000 | 980,000 |
Between 2 and 5 years [Member] | ||
Disclosure of detailed information about borrowings [line items] | ||
Borrowings | 8,984,000 | 5,981,000 |
Total | € 8,984,000 | € 5,981,000 |
Segment Information (Details)
Segment Information (Details) | 12 Months Ended |
Dec. 31, 2018segment | |
Segment Information | |
Number of reportable segment | 1 |
Intangible Assets (Details)
Intangible Assets (Details) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2012 | |
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | € 39,000 | € 90,000 | |
Impairment | (39,000) | ||
Amortization | (51,000) | ||
Movement for the period | (39,000) | (51,000) | |
Carrying amount, end of period | 39,000 | ||
Cost | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | 191,000 | 191,000 | |
Carrying amount, end of period | 191,000 | 191,000 | |
Accumulated depreciation | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | (152,000) | (101,000) | |
Carrying amount, end of period | (191,000) | (152,000) | |
Licences [member] | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | 39,000 | 39,000 | |
Impairment | (39,000) | ||
Movement for the period | (39,000) | ||
Carrying amount, end of period | 39,000 | ||
Licences [member] | Cost | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | 39,000 | 39,000 | |
Additions | € 39,000 | ||
Carrying amount, end of period | 39,000 | 39,000 | |
Licences [member] | Accumulated depreciation | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, end of period | (39,000) | ||
Software | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | 51,000 | ||
Amortization | (51,000) | ||
Movement for the period | (51,000) | ||
Software | Cost | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | 152,000 | 152,000 | |
Carrying amount, end of period | 152,000 | 152,000 | |
Software | Accumulated depreciation | |||
Disclosure of detailed information about intangible assets [line items] | |||
Carrying amount, beginning of period | (152,000) | (101,000) | |
Carrying amount, end of period | € (152,000) | € (152,000) |
Property, Plant and Equipment_3
Property, Plant and Equipment ('PP&E') (Details) | 12 Months Ended | ||
Dec. 31, 2018EUR (€)m² | Dec. 31, 2017EUR (€) | Jan. 31, 2019m² | |
Property, Plant and Equipment | |||
Carrying amount at beginning of period | € 2,505,000 | € 3,438,000 | |
Property, Plant and Equipment | 2,505,000 | 3,438,000 | |
Additions | 312,000 | 82,000 | |
Depreciation | 953,000 | 1,015,000 | |
Movement for the period | (641,000) | (933,000) | |
Carrying amount at end of period | € 1,864,000 | 2,505,000 | |
Zernikedreef in Leiden, the Netherlands | |||
Property, Plant and Equipment | |||
Leased facilities | m² | 2,960 | ||
Lease renewal term (in years) | 5 years | ||
Office rental area | m² | 60 | ||
Research and development costs | |||
Property, Plant and Equipment | |||
Depreciation | € 725,000 | 836,000 | |
General and administrative costs | |||
Property, Plant and Equipment | |||
Depreciation | 228,000 | 179,000 | |
Leasehold improvements | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | 1,054,000 | 1,339,000 | |
Property, Plant and Equipment | 1,054,000 | 1,339,000 | |
Additions | 18,000 | 9,000 | |
Depreciation | 296,000 | 294,000 | |
Movement for the period | (278,000) | (285,000) | |
Carrying amount at end of period | 776,000 | 1,054,000 | |
Laboratory equipment | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | 935,000 | 1,297,000 | |
Property, Plant and Equipment | 935,000 | 1,297,000 | |
Additions | 281,000 | 47,000 | |
Depreciation | 419,000 | 409,000 | |
Movement for the period | (138,000) | (362,000) | |
Carrying amount at end of period | 797,000 | 935,000 | |
Other | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | 516,000 | 802,000 | |
Property, Plant and Equipment | 516,000 | 802,000 | |
Additions | 13,000 | 26,000 | |
Depreciation | 238,000 | 312,000 | |
Movement for the period | (225,000) | (286,000) | |
Carrying amount at end of period | 291,000 | 516,000 | |
Cost | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | 5,169,000 | 5,087,000 | |
Property, Plant and Equipment | 5,169,000 | 5,087,000 | |
Carrying amount at end of period | 5,481,000 | 5,169,000 | |
Cost | Leasehold improvements | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | 1,856,000 | 1,847,000 | |
Property, Plant and Equipment | 1,856,000 | 1,847,000 | |
Carrying amount at end of period | 1,874,000 | 1,856,000 | |
Cost | Laboratory equipment | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | 2,004,000 | 1,957,000 | |
Property, Plant and Equipment | 2,004,000 | 1,957,000 | |
Carrying amount at end of period | 2,285,000 | 2,004,000 | |
Cost | Other | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | 1,309,000 | 1,283,000 | |
Property, Plant and Equipment | 1,309,000 | 1,283,000 | |
Carrying amount at end of period | 1,322,000 | 1,309,000 | |
Accumulated depreciation | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | (2,664,000) | (1,649,000) | |
Property, Plant and Equipment | (2,664,000) | (1,649,000) | |
Carrying amount at end of period | (3,617,000) | (2,664,000) | |
Accumulated depreciation | Leasehold improvements | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | (802,000) | (508,000) | |
Property, Plant and Equipment | (802,000) | (508,000) | |
Carrying amount at end of period | (1,098,000) | (802,000) | |
Accumulated depreciation | Laboratory equipment | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | (1,069,000) | (660,000) | |
Property, Plant and Equipment | (1,069,000) | (660,000) | |
Carrying amount at end of period | (1,488,000) | (1,069,000) | |
Accumulated depreciation | Other | |||
Property, Plant and Equipment | |||
Carrying amount at beginning of period | (793,000) | (481,000) | |
Property, Plant and Equipment | (793,000) | (481,000) | |
Carrying amount at end of period | € (1,031,000) | € (793,000) |
Social Security and Other Tax_3
Social Security and Other Taxes (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Social Security and Other Taxes | ||
Value added tax | € 311 | € 396 |
Wage tax | 932 | |
Total Social Security and Other Taxes | € 1,243 | € 396 |
Prepayments and Other Receiva_3
Prepayments and Other Receivables (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Prepayments and Other Receivables. | ||
Prepayments | € 645 | € 1,991 |
Other receivables | 899 | 73 |
Total Prepayments and Other Receivables | € 1,544 | € 2,064 |
Cash and Cash Equivalents (Deta
Cash and Cash Equivalents (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Cash and Cash Equivalents. | ||||
Cash at banks | € 105,580 | € 48,099 | ||
Total cash and cash equivalents | € 105,580 | € 48,099 | € 59,200 | € 94,865 |
Shareholders_ Equity - Share ca
Shareholders’ Equity - Share capital (Details) | Jun. 28, 2017EUR (€) | Nov. 30, 2018USD ($)$ / sharesshares | Sep. 30, 2018EUR (€) | Nov. 30, 2017EUR (€) | Dec. 31, 2018EUR (€)shares | Dec. 31, 2017EUR (€)shares | Dec. 31, 2016shares | Dec. 31, 2018$ / shares | Dec. 31, 2018EUR (€)shares | Nov. 30, 2018€ / shares | Nov. 07, 2018USD ($) | Sep. 30, 2018$ / sharesshares | Nov. 30, 2017$ / sharesshares | Nov. 30, 2017€ / sharesshares | Jun. 28, 2017$ / sharesshares | Jun. 28, 2017€ / sharesshares | Dec. 31, 2015shares |
Shareholders’ Equity | |||||||||||||||||
Authorized share capital | € | € 7,200,000 | ||||||||||||||||
Maximum aggregate offering of ordinary shares | $ | $ 300,000,000 | ||||||||||||||||
Par value per share | $ / shares | $ 0.04 | ||||||||||||||||
Shares were issued and fully paid in cash | 43,149,987 | ||||||||||||||||
Treasury shares | 4,503,149 | 4,277,051 | |||||||||||||||
Shares issued in the period | € | € 84,191,000 | € 25,685,000 | |||||||||||||||
Ordinary | |||||||||||||||||
Shareholders’ Equity | |||||||||||||||||
Number of shares issued | 36,425,014 | 23,346,856 | 43,149,987 | 23,345,965 | |||||||||||||
Issued for cash | 6,612,500 | 8,573,975 | |||||||||||||||
Issued for services | 112,473 | ||||||||||||||||
Exercise of share options | 226,098 | 1,034 | 891 | ||||||||||||||
Treasury shares issued | (226,098) | 4,503,149 | |||||||||||||||
Number of shares authorised | 90,000,000 | ||||||||||||||||
Preferred | |||||||||||||||||
Shareholders’ Equity | |||||||||||||||||
Number of shares authorised | 90,000,000 | ||||||||||||||||
Market offering program | |||||||||||||||||
Shareholders’ Equity | |||||||||||||||||
Number of shares issued | 976,477 | ||||||||||||||||
Transaction cost | € | € 127,000 | ||||||||||||||||
Net proceeds | € | € 4,138,000 | ||||||||||||||||
Institutional investors | |||||||||||||||||
Shareholders’ Equity | |||||||||||||||||
Number of shares issued | 1,200,000 | 1,200,000 | |||||||||||||||
Share price | (per share) | $ 5 | € 4.40 | |||||||||||||||
Gross proceeds | € | € 5,278,000 | ||||||||||||||||
Transaction cost | € | 414,000 | ||||||||||||||||
Net proceeds | € | € 4,864,000 | ||||||||||||||||
Underwritten public offering and direct offering | |||||||||||||||||
Shareholders’ Equity | |||||||||||||||||
Number of shares issued | 6,612,500 | 6,397,498 | 6,397,498 | ||||||||||||||
Share price | (per share) | $ 15.75 | $ 3.25 | € 2.76 | ||||||||||||||
Gross proceeds | € | € 89,983,000 | € 17,671,000 | |||||||||||||||
Transaction cost | € | 5,792,000 | 988,000 | |||||||||||||||
Net proceeds | € | € 84,191,000 | € 16,683,000 | |||||||||||||||
H.C. Wainwright & Co | Ordinary | |||||||||||||||||
Shareholders’ Equity | |||||||||||||||||
Maximum aggregate offering of ordinary shares | $ | $ 75,000,000 | ||||||||||||||||
Ionis Pharmaceuticals, Inc | Worldwide License Agreement | |||||||||||||||||
Shareholders’ Equity | |||||||||||||||||
Number of shares issued | 112,473 | ||||||||||||||||
Maximum aggregate offering of ordinary shares | $ | $ 2,500,000 | ||||||||||||||||
Share price | (per share) | $ 22.23 | € 19.46 | |||||||||||||||
Percent of net sales royalties | 20.00% |
Shareholders_ Equity - Share op
Shareholders’ Equity - Share options (Details) - Stock options | 12 Months Ended | ||
Dec. 31, 2018EUR (€)Y | Dec. 31, 2017EUR (€)Y | Dec. 31, 2016EUR (€)Y | |
Shareholders’ Equity | |||
Compensation expenses | € 3,224,000 | € 4,024,000 | € 2,454,000 |
Compensation expenses recorded in general and administrative costs | 2,167,000 | 2,059,000 | 1,480,000 |
Compensation expenses recorded in research and development costs | € 1,057,000 | € 1,965,000 | € 974,000 |
Vesting period | 4 years | ||
Vesting period percentage | 25.00% | ||
Term options | 10 years | ||
Risk-free interest rate | 2.223% | 1.913% | 1.467% |
Expected volatility | 80.90% | 88.70% | 86.30% |
Expected life in years | Y | 5 | 5 | 5 |
Shareholders_ Equity - Movement
Shareholders’ Equity - Movements in the number of options outstanding (Details) - Stock options | 12 Months Ended | ||
Dec. 31, 2018USD ($)EquityInstrumentsY | Dec. 31, 2017USD ($)EquityInstrumentsY | Dec. 31, 2016USD ($)EquityInstrumentsY | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Weighted average fair value per stock option | $ 2.02 | $ 3.21 | $ 3.72 |
Term options | 10 years | ||
Option life, share options granted | Y | 5 | 5 | 5 |
Stock options outstanding, beginning of year (in shares) | EquityInstruments | 3,331,875 | 2,205,989 | 1,108,935 |
Granted (in shares) | EquityInstruments | 1,570,366 | 1,199,447 | 1,214,126 |
Forfeited (in shares) | EquityInstruments | (142,467) | (72,527) | (116,181) |
Exercised (in shares) | EquityInstruments | (226,098) | (1,034) | (891) |
Lapsed (in shares) | EquityInstruments | (22,164) | ||
Stock options outstanding, end of the year (in shares) | EquityInstruments | 4,511,512 | 3,331,875 | 2,205,989 |
Exercisable stock options, end of the year (in shares) | EquityInstruments | 1,683,731 | 1,148,893 | 615,246 |
Stock options outstanding, beginning of year (in dollars per share) | $ 4.78 | $ 4.88 | $ 4.19 |
Granted (in dollars per share) | 3.11 | 4.63 | 5.49 |
Forfeited (in dollars per share) | 4.29 | 5.56 | 4.64 |
Exercised (in dollars per share) | 4.02 | 3.54 | 2.38 |
Lapsed (in dollars per share) | 6 | ||
Stock options outstanding, end of the year (in dollars per share) | $ 4.24 | $ 4.78 | $ 4.88 |
Weighted average life | Y | 7.6 | 7.9 | 8.3 |
Options exercised during the year | $ 15.36 | $ 4.32 | $ 4.23 |
Minimum | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Exercise price | 1.11 | 1.11 | 1.11 |
Maximum | |||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||
Exercise price | $ 20.34 | $ 20.34 | $ 20.34 |
Non-current liabilities (Detail
Non-current liabilities (Details) - EUR (€) | Sep. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 10, 2018 |
Non Current Liabilities [Line Items] | ||||||
Innovation credit | € 5,164,000 | € 4,899,000 | ||||
Convertible loans | 1,871,000 | 662,000 | ||||
Accrued interest | 2,351,000 | 1,683,000 | ||||
Total borrowings | 9,386,000 | 7,244,000 | ||||
Current portion | (1,960,000) | |||||
Non Current portion | 9,386,000 | 5,284,000 | ||||
Research and development expense | € 29,514,000 | € 31,153,000 | € 31,923,000 | |||
Convertible Loans [Member] | ||||||
Non Current Liabilities [Line Items] | ||||||
Total borrowings | € 260,000 | |||||
Interest-bearing rate of credit | 3.00% | 8.00% | ||||
Period to convert into variable number of ordinary shares | 36 months | |||||
Discount rate | 25.00% | |||||
Premium rate | 25.00% | |||||
Percent of total number of ordinary shares outstanding immediately prior to the entry into the Loan | 0.50% | |||||
Convertible Loans [Member] | Minimum | ||||||
Non Current Liabilities [Line Items] | ||||||
Period after which unconverted loans become payable on demand | 24 months | |||||
Convertible Loans [Member] | Maximum | ||||||
Non Current Liabilities [Line Items] | ||||||
Period after which unconverted loans become payable on demand | 36 months | |||||
Dutch Government Innovation Credit RVO Agency [member] | ||||||
Non Current Liabilities [Line Items] | ||||||
Innovation credit | € 5,000,000 | € 4,700,000 | ||||
Total borrowings | € 7,400,000 | |||||
Percentage of costs incurred covered by government innovation credit | 35.00% | |||||
Interest-bearing rate of credit | 10.00% | |||||
Waiver period (in years) | 3 years | |||||
Amount received | € 163,000 | |||||
Interest rate (as percent) | 10.00% | |||||
Dutch Government Innovation Credit RVO Agency [member] | Maximum | ||||||
Non Current Liabilities [Line Items] | ||||||
Research and development expense | € 5,000,000 |
Current Liabilities (Details)
Current Liabilities (Details) - EUR (€) € in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Current Liabilities. | ||
Borrowings | € 1,960 | |
Trade payables | € 135 | 546 |
Social securities and other taxes | 1,019 | |
Pension premiums | 7 | |
Deferred income | 545 | 347 |
Accrued expenses and other liabilities | 7,473 | 4,622 |
Current liabilities | € 8,160 | € 8,494 |
Other income (Details)
Other income (Details) € in Thousands, $ in Thousands | 12 Months Ended | |||||
Dec. 31, 2018USD ($) | Dec. 31, 2018EUR (€) | Dec. 31, 2017USD ($) | Dec. 31, 2017EUR (€) | Dec. 31, 2016USD ($) | Dec. 31, 2016EUR (€) | |
Other income | ||||||
Grant income | $ 5,378 | $ 870 | $ 1,632 | |||
Rental income from property subleases | 174 | 625 | 196 | |||
Other income | 209 | |||||
Total other income | $ 5,761 | € 5,761 | $ 1,495 | € 1,495 | $ 1,828 | € 1,828 |
Other income - Narrative (Detai
Other income - Narrative (Details) - USD ($) $ in Millions | Jun. 05, 2018 | Dec. 31, 2018 | Feb. 09, 2018 | Dec. 31, 2015 |
Other Income [Line Items] | ||||
Contribution received to support clinical development | $ 1.3 | |||
EC Horizon 2020 Program | ||||
Other Income [Line Items] | ||||
Amount of funds available for qualified projects | $ 80,000 | |||
Foundation Fighting Blindness | ||||
Other Income [Line Items] | ||||
Amount of funds available for qualified projects | $ 7.5 | |||
Contribution received to support clinical development | 2.5 | |||
EBRP and EBMRF | ||||
Other Income [Line Items] | ||||
Amount of funds available for qualified projects | $ 5 | |||
Contribution received to support clinical development | $ 1.3 | |||
Clinical support agreement | ||||
Other Income [Line Items] | ||||
Amount of funds available for qualified projects | 4.6 | |||
Clinical support agreement | Entity And Academic Partners [member] | ||||
Other Income [Line Items] | ||||
Amount of funds available for qualified projects | $ 6 | |||
Clinical support agreement | EBRP and EBMRF | ||||
Other Income [Line Items] | ||||
Contribution received to support clinical development | $ 5 |
Research and Development Costs
Research and Development Costs (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Research and Development Costs | |||
Research and development costs | € 29,514 | € 31,153 | € 31,923 |
Employee Benefits (Details)
Employee Benefits (Details) | 12 Months Ended | ||
Dec. 31, 2018EUR (€)employee | Dec. 31, 2017EUR (€)employee | Dec. 31, 2016EUR (€)employee | |
Employee Benefits | |||
Wages and salaries | € 11,558,000 | € 11,855,000 | € 10,184,000 |
Social security costs | 1,346,000 | 1,285,000 | 1,093,000 |
Pension costs — defined contribution plans | 868,000 | 860,000 | 764,000 |
Equity-settled share based payments | 3,224,000 | 4,024,000 | 2,454,000 |
Total employee benefits expense | € 16,996,000 | € 18,024,000 | € 14,495,000 |
Average number of employees for the period | employee | 127.7 | 139.9 | 133.4 |
Research and Development | employee | 89.2 | 96.2 | 100.4 |
General and Administrative | employee | 29.6 | 34 | 32.9 |
Total number of employees at December 31 (converted to FTE) | employee | 118.8 | 130.2 | 133.3 |
WBSO subsidies received for wages and salaries | € 1,294,000 | € 723,000 | € 807,000 |
Netherlands | |||
Employee Benefits | |||
Total number of employees at December 31 (converted to FTE) | employee | 112.8 | 125.2 |
Financial Income and Expense (D
Financial Income and Expense (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Financial Income and Expense | |||
Current accounts and deposits | € 189 | € 90 | € 270 |
Interest on loans and borrowings | (810) | (596) | (538) |
Net foreign exchange benefit/(loss) | (171) | (2,669) | 738 |
Total | € (792) | € (3,175) | € 470 |
Income Taxes (Details)
Income Taxes (Details) € in Thousands, $ in Thousands | 12 Months Ended | |||||
Dec. 31, 2018USD ($) | Dec. 31, 2018EUR (€) | Dec. 31, 2017USD ($) | Dec. 31, 2017EUR (€) | Dec. 31, 2016USD ($) | Dec. 31, 2016EUR (€) | |
Income Taxes | ||||||
Income tax based on domestic rate | $ 9,106 | $ 10,918 | $ 9,776 | |||
Non-deductible expenses | (818) | (634) | (622) | |||
Deductible expenses | 1,448 | |||||
Tax incentives | (46) | |||||
Current year losses for which no deferred tax asset was recognized | (9,710) | (10,257) | (9,045) | |||
Change in unrecognized deductible temporary differences | (25) | (25) | $ (63) | |||
Income tax charge | $ 1 | € 1 | $ 2 | € 2 | ||
Effective tax rate | ||||||
Provision for tax | € | € 0 | |||||
Significant temporary differences | € | 0 | |||||
Tax loss carry-forwards | € | € 162,600 | € 123,900 | € 82,900 |
Earnings Per Share (Details)
Earnings Per Share (Details) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Earnings Per Share | |||
Result attributable to equity holders of the company (€ in thousands) | € (36,894) | € (43,637) | € (39,103) |
Weighted average number of shares outstanding | 34,052,520 | 25,374,807 | 23,346,507 |
Basic (and diluted) earnings per share (€ per share) | € (1.08) | € (1.72) | € (1.67) |
Operating Leases - Minimum leas
Operating Leases - Minimum lease payments under non-cancellable operating leases (Details) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Operating Lease by minimum lease payments payable under noncancellable operating leases | |||
Lease expenditure | € 1,813,000 | € 2,103,000 | € 1,849,000 |
Future aggregate minimum lease payments under non-cancellable operating leases | 2,466,000 | 4,919,000 | 7,283,000 |
Less than 1 year | |||
Operating Lease by minimum lease payments payable under noncancellable operating leases | |||
Future aggregate minimum lease payments under non-cancellable operating leases | 1,233,000 | 1,607,000 | 1,775,000 |
Between 1 and 5 years | |||
Operating Lease by minimum lease payments payable under noncancellable operating leases | |||
Future aggregate minimum lease payments under non-cancellable operating leases | € 1,233,000 | € 3,312,000 | € 5,508,000 |
Operating Leases - Minimum le_2
Operating Leases - Minimum lease payments under non-cancellable leases are receivable (Details) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Operating lease by minimum lease payments receivable under noncancellable operating lease | |||
Total sublease income | € 174,000 | € 625,000 | € 196,000 |
Future minimum lease payments under non-cancellable leases are receivable | 174,000 | 463,000 | |
Less than 1 year | |||
Operating lease by minimum lease payments receivable under noncancellable operating lease | |||
Future minimum lease payments under non-cancellable leases are receivable | € 174,000 | € 463,000 |
Commitments and Contingencies -
Commitments and Contingencies - Claims and Patent License Agreement (Details) | Oct. 26, 2018USD ($) | Jan. 31, 2018 | Jun. 30, 2015 | Apr. 30, 2014 | Dec. 31, 2018EUR (€)claim | Dec. 31, 2017EUR (€) | Dec. 31, 2012USD ($) | Dec. 31, 2012EUR (€) |
Commitments and Contingencies | ||||||||
Shares issued in the period | € | € 84,191,000 | € 25,685,000 | ||||||
Claims known to management related to activities of company | claim | 0 | |||||||
Ionis Pharmaceuticals, Inc | ||||||||
Commitments and Contingencies | ||||||||
Ownership interest | 18.50% | |||||||
Ionis Pharmaceuticals, Inc | Stock Purchase Agreement [Member] | ||||||||
Commitments and Contingencies | ||||||||
Shares issued in the period | $ 2,500,000 | |||||||
Ownership interest | 19.90% | |||||||
Period prohibiting for disposition of ordinary shares issued | 12 months | |||||||
Ionis Pharmaceuticals, Inc | Maximum | License Agreement [Member] | ||||||||
Commitments and Contingencies | ||||||||
Upfront payment | $ 6,000,000 | |||||||
Certain payments upon satisfaction of certain development and sales milestones | $ 20,000,000 | |||||||
Radboud University Medical Center [Member] | License Agreement [Member] | ||||||||
Commitments and Contingencies | ||||||||
Threshold period for terminating agreement in case of default not cured | 30 days | |||||||
Radboud University Medical Center [Member] | Patent license agreement | ||||||||
Commitments and Contingencies | ||||||||
Threshold period for terminating agreement in case of default not cured | 30 days | |||||||
Radboud University Medical Center [Member] | Minimum | License Agreement [Member] | ||||||||
Commitments and Contingencies | ||||||||
Threshold period for terminating agreement in case payment remains outstanding after receiving notice of the amount due | 30 days | |||||||
Radboud University Medical Center [Member] | Minimum | Patent license agreement | ||||||||
Commitments and Contingencies | ||||||||
Threshold period for terminating agreement in case payment remains outstanding after receiving notice of the amount due | 30 days | |||||||
Inserm Transfert SA and Assistance [Member] | License Agreement [Member] | ||||||||
Commitments and Contingencies | ||||||||
Term of agreement after the first commercial sale of a product in the country in which the product is sold | 5 years | |||||||
Period for voluntary or involuntary winding-up proceedings or judicial recovery if sublicensees interrupt development activities | 1 year | |||||||
Period for voluntary or involuntary winding-up proceedings or judicial recovery if sublicensees interrupt commercialization | 12 months | |||||||
Period for voluntary or involuntary winding-up proceedings or judicial recovery if the entity does not commercialize a product following to obtaining of marketing approval in a country | 2 years | |||||||
Period for voluntary or involuntary winding-up proceedings or judicial recovery if the entity do not put a product into commercial use and do not keep products reasonably available to the public | 12 years | |||||||
General Hospital Corporation (MGH) [Member] | Patent license agreement | ||||||||
Commitments and Contingencies | ||||||||
Milestone payment on achievement of development and regulatory milestones | $ 700,000 | € 611,000 | ||||||
Annual license fee | $ 10,000 | € 9,000 | ||||||
Royalty percentage | 2.00% | 2.00% |
Commitments and Contingencies_2
Commitments and Contingencies - Clinical support agreements (Details) $ in Millions | Jun. 05, 2018USD ($)installment | Feb. 09, 2018USD ($) | Feb. 09, 2018EUR (€) | Aug. 31, 2014USD ($) | Aug. 31, 2014EUR (€) | Dec. 31, 2018USD ($)installment | Dec. 31, 2018EUR (€)installment | Dec. 31, 2017EUR (€) |
Commitments and Contingencies | ||||||||
Contribution to support clinical development | $ 1.3 | |||||||
Research and development commitments | € | € 8,114,000 | € 7,704,000 | ||||||
Less than 1 year | ||||||||
Commitments and Contingencies | ||||||||
Research and development commitments | € | 5,807,000 | |||||||
Foundation Fighting Blindness | ||||||||
Commitments and Contingencies | ||||||||
Contribution to support clinical development | 2.5 | |||||||
EBRP and EBMRF | ||||||||
Commitments and Contingencies | ||||||||
Contribution to support clinical development | 1.3 | |||||||
Clinical support agreement | Cystic Fibrosis Foundation Therapeutics Inc | ||||||||
Commitments and Contingencies | ||||||||
Milestone payment on achievement of first commercial sale | $ 16 | € 14,000,000 | ||||||
Number of milestone payment installments | 3 | 3 | ||||||
Contribution to support clinical development | $ 3 | € 2,600,000 | ||||||
Milestone payment on achievement of net sales exceeding threshold limit | $ 3 | € 2,600,000 | ||||||
Threshold sales for milestone payment | 500 | 437,000,000 | ||||||
Milestone payment on transfer, sells or licenses other than for clinical or development purposes | $ 6 | € 5,000,000 | ||||||
Period after first commercial sale for payment of first installment | 90 days | 90 days | ||||||
Clinical support agreement | Foundation Fighting Blindness | ||||||||
Commitments and Contingencies | ||||||||
Milestone payment on achievement of first commercial sale | $ 37.5 | € 32,800,000 | ||||||
Number of milestone payment installments | installment | 4 | 4 | ||||||
Milestone payment on transfer, sells or licenses other than for clinical or development purposes | $ 15 | € 13,100,000 | ||||||
Period after first commercial sale for payment of first installment | 60 days | 60 days | ||||||
Clinical support agreement | EBRP and EBMRF | ||||||||
Commitments and Contingencies | ||||||||
Contribution to support clinical development | $ 5 | |||||||
Number of equal semi-annual installments | installment | 12 | |||||||
Return on investment payable | 1 | |||||||
Sales milestone | $ 100 | |||||||
Percentage of payment to be made in the event of disposition | 33.30% | |||||||
Number of times, amount awarded, not to exceed | 4 | |||||||
Clinical support agreement | EBRP and EBMRF | Less than 1 year | ||||||||
Commitments and Contingencies | ||||||||
Return on investment payable | 1.36 | |||||||
Clinical support agreement | EBRP and EBMRF | Later than one year and not later than two years [member] | ||||||||
Commitments and Contingencies | ||||||||
Return on investment payable | 1.36 | |||||||
Clinical support agreement | EBRP and EBMRF | Later than two years and not later than three years [member] | ||||||||
Commitments and Contingencies | ||||||||
Return on investment payable | 1.36 | |||||||
Minimum | ||||||||
Commitments and Contingencies | ||||||||
Research And Commitments Period | 1 year | 1 year | ||||||
Maximum | ||||||||
Commitments and Contingencies | ||||||||
Research And Commitments Period | 5 years | 5 years | ||||||
Entering into partnership | Clinical support agreement | Foundation Fighting Blindness | ||||||||
Commitments and Contingencies | ||||||||
Contribution to support clinical development | $ 7.5 | € 6,600,000 |
Related-Party Transactions - Co
Related-Party Transactions - Compensation (Details) - EUR (€) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Supervisory Board | |||
Transactions between the Company and related parties | |||
Short term employee benefits | € 252,000 | € 288,000 | € 287,000 |
Share-based payment | 217,000 | 438,000 | 204,000 |
Total compensation | 469,000 | 726,000 | 491,000 |
Mr. Dinko Valerio | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 36,000 | 36,000 | 36,000 |
Share-based payment | 69,000 | 87,000 | 52,000 |
Total compensation | 105,000 | 123,000 | 88,000 |
Mr. Henri Termeer | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 28,000 | 31,000 | |
Share-based payment | 160,000 | 51,000 | |
Total compensation | 188,000 | 82,000 | |
Mr. Antoine Papiernik | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 72,000 | 76,000 | 78,000 |
Total compensation | 72,000 | 76,000 | 78,000 |
Ms. Alison Lawton | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 31,000 | 31,000 | 31,000 |
Share-based payment | 75,000 | 99,000 | 74,000 |
Total compensation | 106,000 | 130,000 | 105,000 |
Mr. Paul Baart | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 80,000 | 84,000 | 82,000 |
Total compensation | 80,000 | 84,000 | 82,000 |
Mr. James Shannon | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 33,000 | 33,000 | 29,000 |
Share-based payment | 73,000 | 92,000 | 27,000 |
Total compensation | 106,000 | 125,000 | 56,000 |
Key management personnel | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 3,261,000 | 2,700,000 | 1,795,000 |
Post-employment benefits | 89,000 | 89,000 | 68,000 |
Share-based payment | 2,131,000 | 2,307,000 | 1,175,000 |
Total compensation | 5,481,000 | 5,096,000 | 3,038,000 |
Management Board | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 1,535,000 | 981,000 | 775,000 |
Post-employment benefits | 25,000 | 23,000 | 20,000 |
Share-based payment | 1,132,000 | 883,000 | 556,000 |
Total compensation | 2,692,000 | 1,887,000 | 1,351,000 |
Mr. D.A. de Boer | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 726,000 | 570,000 | 429,000 |
Post-employment benefits | 9,000 | 8,000 | 7,000 |
Share-based payment | 668,000 | 622,000 | 391,000 |
Total compensation | 1,403,000 | 1,200,000 | 827,000 |
Mr. R.K. Beukema | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 809,000 | 411,000 | 346,000 |
Post-employment benefits | 16,000 | 15,000 | 13,000 |
Share-based payment | 464,000 | 261,000 | 165,000 |
Total compensation | 1,289,000 | 687,000 | 524,000 |
Senior Management | |||
Transactions between the Company and related parties | |||
Short term employee benefits | 1,726,000 | 1,719,000 | 1,020,000 |
Post-employment benefits | 64,000 | 66,000 | 48,000 |
Share-based payment | 999,000 | 1,424,000 | 619,000 |
Total compensation | € 2,789,000 | € 3,209,000 | € 1,687,000 |
Related-Party Transactions - St
Related-Party Transactions - Stock options (Details) | Sep. 12, 2017 | Dec. 31, 2018EUR (€)Optionsiteminstallmentshares | Dec. 31, 2017EUR (€)Options | Dec. 31, 2016EUR (€)Options |
Sofinnova Capital VII FCPR | ||||
Transactions between the Company and related parties | ||||
Number of ordinary shares outstanding | shares | 2,764,194 | |||
Mr. Valerio | ||||
Transactions between the Company and related parties | ||||
Number of ordinary shares outstanding | shares | 1,043,420 | |||
Number of options outstanding | 115,925 | |||
Number of options granted | 27,500 | 32,164 | 23,989 | |
Exercise price of options granted | € | € 2.74 | € 4.65 | € 6.08 | |
Number of tranches | item | 4 | |||
Vesting percentage of options | 25.00% | |||
Borrowings, interest rate | 8.00% | |||
Vesting period | 36 months | |||
Period after which unconverted loans become payable on demand | 24 months | |||
Ms. Alison Lawton | ||||
Transactions between the Company and related parties | ||||
Number of options outstanding | 96,473 | |||
Number of options granted | 27,500 | 32,164 | 23,989 | |
Exercise price of options granted | € | € 2.74 | € 4.65 | € 6.08 | |
Number of tranches | item | 4 | |||
Vesting percentage of options | 25.00% | |||
Mr. James Shannon | ||||
Transactions between the Company and related parties | ||||
Number of ordinary shares outstanding | shares | 61,538 | |||
Number of options outstanding | 92,733 | |||
Number of options granted | 27,500 | 32,164 | 33,069 | |
Exercise price of options granted | € | € 2.74 | € 4.65 | € 4.32 | |
Number of tranches | item | 4 | |||
Vesting percentage of options | 25.00% | |||
Mr. D.A. de Boer | ||||
Transactions between the Company and related parties | ||||
Number of ordinary shares outstanding | shares | 705,309 | |||
Number of options outstanding | 828,623 | |||
Number of options granted | 379,285 | 239,717 | 129,727 | |
Exercise price of options granted | € | € 2.74 | € 4.65 | € 6.64 | |
Number of tranches | installment | 4 | |||
Bonus based on goals realised | € | € 281,000 | € 217,000 | € 131,000 | |
Weighted average contractual life of options | 8 years 1 month 6 days | |||
Mr. R.K. Beukema | ||||
Transactions between the Company and related parties | ||||
Number of ordinary shares outstanding | shares | 346,239 | |||
Number of options outstanding | 440,013 | |||
Number of options granted | 140,932 | 101,408 | 50,608 | |
Exercise price of options granted | € | € 2.74 | € 4.65 | € 6.64 | |
Number of tranches | installment | 4 | |||
Bonus based on goals realised | € | € 134,000 | € 113,000 | € 76,000 | |
Severance payment | € | € 324,000 | |||
Weighted average contractual life of options | 7 years 2 months 12 days |
Auditor fees (Details)
Auditor fees (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Auditor fees | |||
Audit fees | € 181 | € 175 | € 165 |
Audit-related fees | 261 | 140 | 39 |
Total | € 442 | € 315 | € 204 |